The Role of microRNAs in Osteoclastogenesis by Franceschetti, Tiziana
University of Connecticut
OpenCommons@UConn
Doctoral Dissertations University of Connecticut Graduate School
1-31-2014
The Role of microRNAs in Osteoclastogenesis
Tiziana Franceschetti
University of Connecticut - Storrs, t.franceschetti@gmail.com
Follow this and additional works at: https://opencommons.uconn.edu/dissertations
Recommended Citation
Franceschetti, Tiziana, "The Role of microRNAs in Osteoclastogenesis" (2014). Doctoral Dissertations. 312.
https://opencommons.uconn.edu/dissertations/312
 The Role of microRNAs in Osteoclastogenesis 
Tiziana Franceschetti, Ph.D. 
University of Connecticut, 2014 
 
ABSTRACT 
 
microRNAs (miRNAs) are short sequences of RNA that function as negative 
post-transcriptional regulators of gene expression. Their effects are mediated through 
direct binding to target messenger RNAs. Studies describing the crucial role of miRNAs 
in osteoclasts are quite limited. The aim of this work was to investigate the basic 
mechanisms by which miRNAs control osteoclast differentiation and activity. 
miR-29 Promotes Murine Osteoclastogenesis by Regulating Osteoclast 
Commitment and Migration. The expression of miR-29 family members increases during 
osteoclast differentiation, and its inhibition impairs commitment and migration of the 
progenitors. In an effort to understand how miR-29 exerts its function, we demonstrated 
that miR-29 negatively regulates RNAs critical for cytoskeletal organization and RNAs 
expressed in the macrophage lineage, as well as Calcitonin receptor, which controls 
osteoclast survival and resorption. 
Pathway analysis of microRNA expression profile during murine 
osteoclastogenesis. Microarray analysis was used to profile the expression of miRNAs 
during the course of osteoclast differentiation, in an enriched population of osteoclast 
Tiziana Franceschetti - University of Connecticut, 2014 
progenitor cells from murine bone marrow. Computational analyses were used to predict 
functional pathways that may be regulated by clusters of miRNAs in osteoclasts. The 
most prominent pathways identified include those involved in cell motility, cell-matrix 
interactions, axon guidance, and cytoskeletal remodeling. These processes are critical for 
the migration of osteoclast precursors, their maturation, and bone resorbing activity. 
These studies contribute to our understanding of miRNA function in the 
osteoclast lineage. This information could be used to develop therapies for skeletal 
diseases associated to alterations in the bone resorption compartment. 
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CHAPTER 1: 
INTRODUCTION 
Osteoclast Biology and Regulation by microRNAs 
 
Bone is a highly dynamic tissue, continuously remodeling itself to repair damaged 
bone matrix and to fulfill the metabolic needs of the organism. Bone remodeling is 
achieved through a delicate balance between bone formation, which is mediated by 
osteoblasts, and bone resorption, which is accomplished by osteoclasts (1). Specific 
factors are produced by osteoblasts and osteoclasts to ensure that bone resorption is 
coupled to bone formation during physiological bone remodeling, to preserve the 
microarchitecture of bone. Continuous cell-cell communication between osteoblasts and 
osteoclasts, through physical interaction and exchange of soluble factors, allows the bone 
cells to regulate each other’s differentiation and activity. 
Bone is remodeled to respond to hormonal cues or when nutritional modifications 
require mobilization of minerals from the skeleton. Furthermore, skeletal remodeling can 
regulate proliferation and differentiation of the cells of the bone marrow niche, a stem 
cell-rich compartment that is comprised of numerous hematopoietic and mesenchymal 
progenitors. Therefore, skeletal homeostasis is critical for the maintenance of bone 
health. 
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Alterations in osteoclast differentiation or resorption activity can lead to an 
imbalance in the bone remodeling compartment, which is associated with the 
development or progression of debilitating pathological conditions. These include 
osteoporosis, osteopetrosis, rheumatoid arthritis, and multiple myeloma (2-7). Decoding 
the complex regulatory pathways that underlie osteoclast differentiation and activity is a 
crucial step in the development of new therapeutic strategies to treat disorders of bone 
remodeling. Considerable research efforts have contributed to characterizing the 
processes that regulate osteoclastogenesis and bone resorption at the transcriptional and 
post-translational levels. 
 microRNAs (miRNAs) are a rather novel class of regulators of gene expression, 
and they control key cellular processes, including differentiation, proliferation, and 
survival. miRNAs are short (20-25 nucleotide-long), single-stranded sequences of RNA, 
which post-transcriptionally inhibit the expression of specific target genes (8). The 
importance of miRNAs in skeletal biology has been extensively investigated, with 
particular focus on osteoblasts and chondrocytes (9). However, the role of specific 
miRNAs in the osteoclast lineage is still widely uncharacterized. 
The goal of this Introduction is to summarize our knowledge of the mechanisms 
regulating osteoclast differentiation and activity, and describe the most recent studies on 
the role of miRNAs in the osteoclast. 
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I. Osteoclasts. 
I.1. Osteoclast differentiation. 
Osteoclasts are specialized cells that resorb bone, and their differentiation is an 
intricate, multi-step process (Figure 1.1). Osteoclasts derive from multipotential 
hematopoietic precursors, which can also give rise to erythrocytes, platelets, and cells of 
the immune system. Osteoclastogenesis initiates with the differentiation of common 
myeloid progenitors, which 
can form monocytes-
macrophages, granulocytes, 
and megakaryocytes. In 
response to a number of 
osteoclastogenic stimuli, 
monocyte precursors 
proliferate, migrate, and 
commit to the osteoclast 
lineage, at the expense of 
the alternative macrophage 
fate. Osteoclast precursors 
then fuse into a 
multinucleated polykaryon, 
which can be activated to 
 
Figure 1.1. The process of osteoclastogenesis. 
Schematic representation of the various phases of 
osteoclast differentiation. Key transcriptional regulators 
and marker genes of each step are indicated. 
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resorb bone, triggering the bone remodeling process (2, 10). Although multinucleation is 
not necessary for bone degradation, it was shown that resorption efficiency is directly 
proportional to size of the mature osteoclast. The activated osteoclast has a limited life 
span, and will physiologically undergo apoptosis, to protect the skeleton from excessive 
bone resorption. 
 
I.2. Osteoclast function. 
Osteoclasts adhere to the bone surface through the interaction of integrin αvβ3 
with Arg-Gly-Asp (RGD) motifs on extracellular matrix proteins, such as osteopontin 
and bone sialoprotein. Mature, activated osteoclasts then need to become polarized in 
order to begin the resorption process (Figure 1.1). To accomplish this, osteoclasts 
perform an extensive reorganization of the cytoskeleton (11, 12). Polarized osteoclasts, 
rich in mitochondria that produce energy necessary for resorption, position the nuclei in 
the apical part of the cell. In contrast, in the basal region, cytoskeletal remodeling allows 
the formation of specialized, actin-rich structures, called podosomes, used by the 
osteoclasts to attach to the bone matrix (Figure 1.1). Here, actin filaments interact with 
cytoskeletal proteins, including α-actinin and vinculin. The arrangement of several 
podosomes into a dynamic circular structure (podosome belt) leads to the formation of 
the sealing zone, which creates an isolated extracellular compartment, known as the bone 
resorption lacuna (11, 13, 14). 
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The basolateral membrane of the polarized osteoclast, called the ruffled border, is 
responsible for resorption. This is achieved by establishing an acidic environment in the 
resorption lacuna, with the combined action of carbonic anhydrase II, H+/ATPase proton 
pumps, ClC-7 chloride channels, and HCO3
-/Cl- exchangers. Carbonic anhydrase initiates 
the acidification process by producing protons and HCO3
-, as a result of CO2 hydration 
(15). By means of secretory vesicles and H+/ATPase pumps, H+ ions are transported 
through the ruffled border into the resorption pit (16). Vacuolar H+/ATPase works in 
combination with ClC-7 channels to secrete Cl- ions into the resorptive 
microenvironment (16). Energy-independent HCO3
-/Cl- exchangers, located in the apical 
membrane of the osteoclast, are responsible of maintaining the intracellular pH (17). The 
acidification step is necessary to dissolve the inorganic components of the extracellular 
mineralized matrix. 
Different matrix proteases, such as matrix metalloproteinase 9 (MMP-9) and 
tartrate resistant acid phosphatase (TRAP), participate in the degradation of extracellular 
matrix proteins (Figure 1.1) (18, 19). However, a major role is played by Cathepsin K, a 
cysteine protease that is also secreted through the ruffled border, which degrades the 
organic constituents of bone, comprised primarily by type I collagen fibers (Figure 1.1) 
(4). The degradation products are endocytosed by the resorbing osteoclast, transported at 
the apical membrane, and secreted into the extracellular compartment. 
Bone resorption is very dynamic, and consists of cycles of osteoclast adhesion to 
the bone surface, matrix degradation, and detachment. In a controlled manner, osteoclasts 
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continuously reorganize the actin cytoskeleton into lamellipodia to migrate on the bone 
surface, and to form new sealing zones, until they undergo apoptosis (11). 
 
I.3. Regulation of osteoclast differentiation and function. 
 Osteoclast differentiation, activation, and survival are tightly regulated by a 
combination of pro- and anti-osteoclastogenic hormones and cytokines. Among the pro-
osteoclastogenic factors, Macrophage-colony stimulating factor (M-CSF, CSF1) and 
Receptor activator of nuclear factor kappa-B (NFκB) ligand (RANKL) are essential and 
sufficient for inducing osteoclast differentiation in vitro and in vivo (2, 20). In the 
skeleton, these and other cytokines are produced by cells of the mesenchymal lineage: 
stromal cells, osteoblasts, and osteocytes. However, osteoclast regulation is not limited to 
these non-hematopoietic cells, and in the past decade the importance of immune cells in 
the control of bone resorption has been described (21). Many of the molecules involved 
in regulating osteoclast differentiation and activity were identified through the analysis of 
animal models of naturally occurring genetic mutations, or transgenic gain-of-function or 
loss-of-function mouse models displaying an osteopetrotic phenotype. 
 
M-CSF. 
 M-CSF is a cytokine important for both the macrophage and the osteoclast 
lineages. M-CSF signaling is activated upon binding to its receptor, c-Fms, which is a 
member of the receptor tyrosine kinase (RTK) superfamily (Figures 1.1 and 1.2). M-CSF  
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binding to its receptor triggers the activation of several intracellular pathways, thereby 
exerting its function on the osteoclast precursors. These complex signaling cascades are 
not completely understood, but include activation of c-Src (cellular Src kinase), Syk 
(spleen tyrosine kinase), PI3K (phosphoinositide 3-kinase), and ERK (extracellular 
signal-regulated kinase) pathways (11). 
M-CSF supports the survival and proliferation of the osteoclast precursor cells. 
Further, M-CSF signaling promotes cytoskeletal reorganization and the migration of the 
 
Figure 1.2. Signaling pathways in osteoclast differentiation. This model summarizes 
the main intracellular signaling pathways activated by M-CSF and RANKL during 
osteoclastogenesis.  
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osteoclast precursors. Importantly, M-CSF also activates the expression of the RANK 
receptor on osteoclast progenitors, therefore priming them to respond to RANKL and 
initiate osteoclast differentiation (10). 
 
RANKL. 
 RANKL signals through RANK, a member of the tumor necrosis factor (TNF) 
receptor superfamily, to promote osteoclast commitment, maturation, and survival 
(Figures 1.1 and 1.2). Further, RANKL supports cytoskeletal remodeling, motility, and 
bone resorption activity, thus acting as a key regulator of osteoclast differentiation and 
function. The RANKL/RANK interaction activates the expression of osteoclast marker 
genes, including TRAP, Cathepsin K, integrin β3, and calcitonin receptor (Figure 1.1) (2, 
10, 22). Osteoprotegerin (OPG), also secreted by cells of the osteoblastic lineage and by 
immune cells, is a decoy receptor for RANKL, thus a negative regulator of 
osteoclastogenesis. Frequently, the relative abundance of OPG compared with RANKL 
can determine whether osteoclast formation may ensue (23). 
 Like M-CSF, RANKL signaling is transduced by numerous intracellular 
pathways, upon interaction of RANK with TNFR-associated cytoplasmic factors 
(TRAFs), including TRAF6. In osteoclasts, RANKL mediates the activation, for 
example, of the mitogen-activated protein kinase (MAPK) pathways involving c-Jun N-
terminal kinase (JNK), p38 extracellular kinase (ERF), and ERK, as well as the inhibitor 
of NFκB kinase (IKK) pathway, the PI3K pathway, and the Src pathway (11). 
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Downstream effectors of these signaling cascades include several transcription factors 
critical for the osteoclast lineage. 
 
Transcriptional regulation of osteoclast differentiation. 
Most of the transcription factors involved in the control of osteoclast 
differentiation act as heterodimers to control gene expression. Purine-rich nucleic acid 
binding protein 1 (PU.1) represents the earliest marker for osteoclastogenesis, and is 
essential for the commitment of the myeloid progenitors into macrophage and osteoclast 
precursors (24). Further, PU.1 regulates genes important for osteoclast function, 
including Cathepsin K and osteoclast-associated receptor (Oscar) (Figure 1.1) (25, 26). 
For the most part, PU.1 modulation of gene expression during the initial phases of 
osteoclast differentiation is mediated by its interaction with microphthalmia-associated 
transcription factor (MITF) (Figure 1.1) (26, 27). MITF has also been shown to 
participate in the regulation of the osteoclast genes Clcn7, and osteopetrosis-associated 
transmembrane protein 1 (Ostm1) (28). 
RANKL signaling up-regulates the expression and the activation of NFκB, c-Jun, 
and c-Fos, which are required for osteoclast differentiation and to induce osteoclast 
marker genes (Figures 1.1 and 1.2). The NFκB family of transcription factors functions as 
heterodimers, and are translocated into the nucleus to regulate gene expression (29). c-
Jun and c-Fos belong to the activator protein 1 (AP-1) family, which is composed of 
heterodimers of Fos and Jun proteins (30, 31). Importantly, NFκB, c-Jun, and c-Fos are 
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involved in inducing the initial up-regulation of Nuclear factor of activated T-cells 
cytoplasmic 1 (NFATc1), the master regulator of osteoclastogenesis (30). 
 In addition to RANKL signaling, other co-stimulatory pathways can initiate 
NFATc1 expression during osteoclast differentiation. The RANKL-independent 
pathways include the Ca2+ signaling pathway and the immunoreceptor tyrosine-based 
activation motif (ITAM) proteins DNAX activation protein of 12 kDa (DAP12) and Fc-
receptor common γ-subunit (FcRγ) (32). In the later stages of osteoclastogenesis, 
NFATc1 binds its own promoter to amplify its expression (32).  
NFATc1 is involved in the regulation of several aspects of osteoclast maturation 
and activity (Figures 1.1 and 1.2). Either alone or in association with other transcription 
factors, NFATc1 stimulates the fusion of the precursors into multinucleated cells, through 
the up-regulation of the dendritic cell-specific transmembrane protein (DC-STAMP) and 
the d2 isoform of vacuolar ATPase V0 domain (Atp6v0d2) (32). In addition, NFATc1 
regulates osteoclast migration and adhesion to the bone surface. This is achieved by 
directly promoting the expression of β3 integrin and c-Src, which trigger intracellular 
pathways that converge on the reorganization of the cytoskeleton, orchestrated by small 
GTPases of the Rho family (32). NFATc1 also promotes the expression of proteins 
required for bone resorption: MMP-9, H+/ATPase, ClC-7, Cathepsin K, TRAP, calcitonin 
receptor, and OSCAR (32). 
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Osteoclast interaction with cells of the bone microenvironment. 
As previously mentioned, bone resorption is coupled to bone formation, and 
osteoclast differentiation and activity are strongly regulated in vitro and in vivo by the 
action of cytokines, including M-CSF, RANKL, and OPG, produced by osteoblasts. 
Further, recent reports indicate that RANKL is also expressed at high levels by terminally 
differentiated osteocytes to support osteoclastogenesis (33, 34). Additionally, bi-
directional signaling between osteoblasts and osteoclasts is achieved through the 
interaction of ephrins and ephrin receptors. EphB4 receptors, expressed on the 
osteoblasts, bind ephrin-B2, present of the surface of the osteoclasts. This interaction 
promotes osteoblast differentiation and, at the same time, inhibits osteoclastogenesis (35). 
In the bone marrow niche, osteoclasts are in close relationship with cells of the 
immune system, which can secrete several regulatory cytokines (21). Macrophages 
produce inflammatory factors, including interleukin 1 (IL-1), IL-6, and Tumor necrosis 
factor α (TNFα). Although IL-1 alone cannot induce osteoclastogenesis, it stimulates 
TRAF6 and potentiates the activation of the RANKL signaling pathway (2, 21). 
Moreover, IL-1 promotes RANKL expression on cells of the osteoblast lineage, which 
confirms the tight interaction of the cells within the bone microenvironment (21). TNFα 
is a potent inducer of osteoclastogenesis, and it functions through a RANKL-independent 
mechanism. This was demonstrated by the observation that TNFα-mediated osteoclast 
differentiation is not blocked in the presence of OPG (36). Additionally, hematopoietic 
precursors from RANKL-, RANK-, and TRAF6-null mice can form mature osteoclasts 
when stimulated with TNFα (37). 
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Activated T lymphocytes express RANKL, a pro-osteoclastogenic factor, but also 
Interferon- (IFN-), IL-4, IL-10, IL-12, and IL-14, which are all inhibitory to osteoclast 
differentiation (21). Therefore, the role of T cells on osteoclast differentiation may 
depend on the ratios between these factors in specific biological conditions. Further, in 
rheumatoid arthritis, T cells of the synovium produce large amounts of IL-17, which 
induces RANKL secretion in synovial fibroblasts, and expression of TNFα, IL-1, and IL-
6 in synovial macrophages. These cytokines stimulate osteoclast differentiation, 
promoting bone resorption and joint destruction (21, 38). Further, B lymphocytes are a 
major source of RANKL and OPG in the bone marrow (39, 40).  
The effect of specific cytokines on osteoclastogenesis also depends on the cellular 
environment. For example, IL-7 has a direct inhibitory effect on osteoclastogenesis in 
vitro (41). However, under inflammatory condition, IL-7 production by stromal cells and 
osteoblasts stimulates the secretion of RANKL from T cells, which ultimately supports 
osteoclast differentiation (42). 
 
I.4. Identification of osteoclast precursors. 
 In the perspective of analyzing the mechanisms that orchestrate osteoclast 
differentiation and activity, the use of a primary cell system is important. Peripheral 
blood and bone marrow represent the main reservoirs of primary osteoclast precursors. 
However, both of these sources are highly heterogeneous, which makes difficult the 
analysis of osteoclast-specific mechanisms. In an effort to decrease the heterogeneity of 
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primary cell cultures, several studies have adopted immunological techniques to deplete 
contaminations from other hematopoietic populations. 
Cell surface markers are routinely used to distinguish osteoclast precursors from 
macrophages, dendritic cells, and B and T cells. A population of cells with high 
osteoclastogenic efficiency can be isolated from mouse bone marrow, peripheral blood, 
and spleen, which can be identified as negative for the lymphoid markers B220/CD45R 
and CD3, present of B and T cells, respectively (43). These cells also present negative or 
low expression of CD11b (also known as integrin alpha M, ITGAM), which is expressed 
on several myeloid lineages and natural killer lymphocytes. Osteoclast precursors express 
high levels of c-Fms (CD115) and c-Kit (CD117), a hematopoietic stem cell marker (43, 
44). Additional studies have characterized the surface antigen profile of the osteoclast 
precursors. Recently, osteoclast precursors were identified as CD3-/B220-/CD11b-/low 
cells expressing high levels of Ly6C (lymphocyte antigen 6), a glycoprotein expressed on 
most hematopoietic cells, and CX3CR1, a chemokine receptor expressed by monocytes 
and lymphocytes. These cells appear to be distinct from a population of progenitors that 
can give rise to not only osteoclasts, but also to macrophages and dendritic cells (45).  
Species-specific differences in osteoclast cell surface antigens may also 
complicate their characterization. CD14, a co-receptor for lipopolysaccharide, is a 
commonly used monocyte marker used to isolate human osteoclast precursors (46, 47). 
More recently, the osteoclastogenic potential of human peripheral blood monocytes was 
differentiated based on the expression of DC-STAMP. This study showed that cells with 
high levels of DC-STAMP generate more osteoclasts than the negative population (48). 
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In conclusion, combinations of surface markers are necessary to isolate osteoclast 
precursor cells, in order to further investigate the mechanisms regulating 
osteoclastogenesis and bone resorption. 
 
II. miRNAs. 
II.1. miRNA biogenesis. 
miRNAs are transcribed by RNA polymerase II as independent genes or included 
in introns or exons of protein coding genes (Figure 1.3). miRNA-coding genes are 
regulated similarly to protein-coding genes, and transcriptional control contributes to 
their expression in specific cells, or tissues, or stages of development (8). Long primary 
miRNAs (pri-miRNAs) contain typical hairpin structures, which, for the most part, are 
cleaved by the nuclear endonuclease Drosha and the RNA binding protein DiGeorge 
syndrome critical region gene 8 (DGCR8). The product, a ~60 nucleotide long precursor 
miRNA (pre-miRNA), is exported into the cytoplasm by Exportin 5. Here, pre-miRNAs 
are further cleaved by Dicer and the RNA binding protein transactivation-response RNA-
binding protein (TRBP) into a miRNA duplex (8). 
The miRNA duplex is then loaded onto an Argonaute protein (AGO). Mature 
functional miRNAs can be derived from either the 5′-strand (indicated as -5p), or the 3′-
strand (indicated as -3p), or both strands of the pre-miRNAs (49). For the most part, the 
functional miRNA strand is more abundant than the miRNA* or passenger strand, and 
can be identified as the least thermodynamically stable strand in the complex. The active 
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miRNA strand remains associated with AGO in an RNA-induced silencing complex 
(RISC), which increases its stability, whereas the miRNA* passenger strand is eventually 
degraded. The choice of the active miRNA strand is often tissue- or cell-specific (50). 
The mature miRNA drives the RISC complex to bind target messenger RNA (mRNA) 
sequences. 
 
 
 
Figure 1.3. miRNA biogenesis and activity. Schematic representation of the miRNA 
processing pathway and the primary mechanisms of miRNA-mediated inhibition of 
gene expression. 
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II.2. miRNA function. 
Short, single-stranded mature miRNAs act, for the most part, as post-
transcriptional, negative regulators of gene expression. Inhibition of gene expression is 
mediated by direct binding to complementary sequences located on target mRNAs 
(Figure 1.3). miRNA binding sites are frequently identified in the 3’ untranslated region 
(UTR), although functional sites are recognized in the coding sequence and in the 5’ 
UTR. Inhibition of gene expression is achieved through different mechanisms, depending 
on the degree of complementarity between the miRNA and the target mRNA. Near-
perfect base-pairing frequently leads to the endonucleolytic cleavage of the mRNA 
sequence and its destabilization, followed by degradation. This mechanism is typically 
observed in plants, although it can also occur in mammalian cells (8). 
More frequently, miRNA-target interactions are based primarily on the binding of 
the nucleotides in positions 2-8 of the miRNA sequence, which are known as the “seed 
region”. miRNA interaction with AGO determines the functional seed region. Here, 
miRNA binding leads to the blockage of translational initiation, and mRNA decay upon 
mRNA decapping or deadenylation. Additional features, other than base-pair 
complementarity, contribute to the final outcome of each miRNA-mediated repression of 
gene expression. These include the accessibility of the target site on the mRNA 
secondary structure, the distance of the binding site to the 3’ end of the mRNA, as well as 
the cellular localization and stability of the miRNA (51, 52). 
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II.3. miRNAs in osteoclasts. 
Since they were first discovered, miRNAs have been widely investigated in 
osteoblasts and in chondrocytes, where they are key regulators of skeletal development 
and bone cell differentiation and function (9). In contrast, there are relatively few reports 
on the role of miRNAs in osteoclasts, and a limited number of miRNA-target interactions 
have been examined in this cell type. One major reason for this shortcoming could be that 
the cell systems available for studying the mechanisms regulating osteoclastogenesis 
have several limitations. For example, most of the mechanistic studies aimed at analyzing 
miRNA function are performed using cell lines as tools. However, an immortalized cell 
line for mature osteoclasts is not available, and the existing osteoclast precursor cell lines 
have limited resorption activity. Further, as previously discussed, sources of primary 
osteoclast precursors, such as the bone marrow, are extremely heterogeneous, which 
makes necessary additional steps for cell isolation and sorting. These limitations likely 
contribute to the deficit in our understanding of miRNA function in osteoclasts. 
 
miRNA biogenesis pathway in the osteoclast lineage. 
Initially, two independent studies analyzed the global role of miRNAs in 
osteoclasts, by interfering with components of the miRNA biogenesis pathway. Sugatani 
and colleagues silenced the expression of DGCR8, Dicer1, and Ago2 in vitro in mouse 
primary bone marrow macrophages (BMMs) (53). These proteins are crucial for the 
processing of the miRNA precursors and generation of the active mature miRNAs. 
Knock-down of DGCR8, Dicer1, or Ago2 impaired the RANKL-mediated up-regulation 
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of transcription factors important for osteoclastogenesis, including PU.1, MITF, c-Fos, 
and NFATc1, as well as their recruitment to the NFATc1 and TRAP promoters. Further, 
the expression of the osteoclast markers TRAP, MMP-9, Cathepsin K, Calcitonin 
receptor, and integrin β3 were strongly attenuated by the suppression of the DGCR8, 
Dicer1, or AGO2 levels. Consistently, osteoclast formation and bone resorbing activity 
were decreased upon silencing of DGCR8, Dicer1, or AGO2 (53). These results indicate 
the overall importance of the miRNA processing pathway in the osteoclast lineage. 
In vivo, the role of miRNA biogenesis in osteoclasts was evaluated by generating 
mouse lines with cell type-specific deletion of Dicer. Dicer deletion in myeloid cells, 
using a CD11b promoter-driven cre, induced a mild osteopetrotic phenotype, with an 
increase in bone formation parameters and decreased osteoclast number (53). Similarly, 
Dicer ablation in mature osteoclasts using a Cathepsin K promoter-driven cre resulted in 
increased bone mass, due to reduced osteoclast number (54). Therefore, these in vivo 
phenotypes confirm that the miRNA biogenesis pathway is crucial for osteoclast 
formation, as observed in vitro. 
There is limited understanding of the mechanisms by which miRNAs regulate the 
processes of osteoclast commitment, maturation, and function. Indeed, at the time of this 
writing, only 9 miRNAs have been investigated in the osteoclast lineage (Table 1.1). An 
overview of these miRNAs and their role in osteoclasts will be presented below. 
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miR-223 
miR-223 was the first miRNA with an identified role in osteoclasts. miR-223 
expression is activated by PU.1, a transcription factor crucial in the early stages of 
myeloid differentiation (24, 66). The expression levels of miR-223 are sustained in 
primary bone marrow-derived osteoclast precursors and in the mouse monocytic cell line 
RAW264.7, but decrease in a time-dependent manner during RANKL-driven 
osteoclastogenesis (61, 67). In a study by Sugatani and colleagues, the authors reported 
Table 1.1. miRNAs investigated in the osteoclast lineage. 
miRNA 
Known target 
genes in OCS 
Role 
in 
OCS 
Experimental system References 
miR-124 NFATc1 - BMMs (55) 
miR-146a TRAF6 - PBMCs (56) 
miR-148a MAFB + PBMCs; mouse (57) 
miR-155 MITF; SOCS - RAW264.7; BMMs; mouse (58-60) 
miR-21 PDCD4 + BMMs (61) 
miR-223 NFIA + RAW264.7; BMMs (53) 
miR-29 
CTR, Cdc42, 
srGAP2, NFIA, 
CD93, GPR85 
+ RAW264.7; BMMs 
Chapter 3; 
(62) 
miR-31 RhoA - BMMs (63) 
miR-320a ARF1 +? PBMCs 
Chapter 5; 
(64) 
miR-503 RANK - PBMCs; mouse (65) 
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that inhibition of the mature miR-223 with an antisense oligonucleotide impairs 
osteoclastogenic differentiation in RAW264.7 cells, suggesting that miR-223 supports 
osteoclastogenesis (53). 
The pro-osteoclastogenic role of miR-223 is mediated, in part, through the 
repression of the transcription factor NFI-A (53, 68). Down-regulation of NFI-A is 
required for the differentiation of several hematopoietic cell types, including osteoclasts, 
granulocytes, and monocytes. In contrast, NFIA is up-regulated during erythropoiesis 
(53, 69, 70). Further, NFI-A negatively regulates the expression of the M-CSF receptor, 
which is critical for osteoclast survival, maturation, and activity, as previously discussed 
(12, 69). Therefore, miR-223 promotes osteoclast differentiation, in part, by targeting 
NFIA. 
 
miR-21 
miR-21 expression is also induced by PU.1 and the AP-1 (activator protein 1) 
family member c-Fos, transcription factors important for osteoclast differentiation and 
function (71). miR-21 levels are up-regulated during the course of osteoclast 
differentiation in RAW264.7 cells and in mouse bone marrow macrophages (BMMs) (61, 
67). BMMs lacking key components of the miRNA processing machinery, either DGCR8 
or Dicer, display impaired osteoclastogenesis. Forced over-expression of miR-21 in these 
cells partially rescues their ability to differentiate into mature osteoclasts. Further, knock-
down of miR-21 results in suppressed osteoclast formation and resorption activity of 
bone marrow-derived macrophage cultures (Figure 1.4) (61). 
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miR-21 represses the expression of PDCD4 
(programmed cell death domain 4) in osteoclasts and 
other tissues (61, 72). PDCD4 inhibits the 
transcriptional activity of AP-1 family members, and 
its over-expression robustly suppresses osteoclast 
differentiation and function. Although other post-
transcriptional targets of miR-21 may be involved, 
PDCD4 inhibition represents one mechanism by 
which miR-21 promotes osteoclastogenesis. In 
addition, miR-21 blocks the expression of FasL, an 
estrogen (E2)-induced pro-apoptotic factor, thereby 
protecting osteoclast progenitors and mature 
osteoclasts from estrogen-mediated apoptosis. In a 
regulatory loop, estrogen can inhibit miR-21 biogenesis, to limit its expression and allow 
FasL translation, in order to restrict osteoclast survival (Figure 1.4) (73). 
 
miR-148a 
miR-148a expression is strongly induced during osteoclastogenesis in CD14+ 
human PBMCs (57). Over-expression of miR-148a in human PBMCs, as well as in 
mouse BMMs, stimulates osteoclast differentiation and activity, whereas opposite effects 
are produced by a miR-148a inhibitor. One of the genes that miR-148a regulates in 
osteoclasts is the transcription factor MAFB (V-maf musculoaponeurotic fibrosarcoma 
 
Figure 1.4. The function of 
miR-21 in osteoclasts. The 
diagram summarizes the 
regulatory loops that control the 
expression of the miR-21, a 
pro-osteoclastogenic miRNA. 
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oncogene homolog B) (57). MAFB inhibits the RANKL-driven transcriptional program 
that promotes osteoclast differentiation (74). In vivo, inhibition of miR-148a, using a 
specific oligonucleotide, elevated bone mass by decreasing bone resorption parameters. 
This important in vivo experiment confirms the pro-osteoclastogenic role of this miRNA 
(57). In addition, miR-148a levels are increased in circulating mononuclear cells from 
systemic lupus erythematosus (SLE) patients, who display lower bone mineral density 
(BMD). PBMCs from SLE patients have augmented osteoclastogenic potential, which is 
restrained upon inhibition of miR-148a. Thus, elevated miR-148a likely contributes to the 
increased osteoclastogenesis in SLE patients (57). 
 
miR-31 
RANKL treatment of mouse BMMs induces a strong up-regulation of miR-31, a 
miRNA previously studied in cancer, but not in hematopoietic cells (63, 75). In 
osteoclasts, miR-31 supports actin ring formation and bone resorption. This is achieved 
because miR-31 tightly controls the expression of RhoA, a GTPase critical for 
cytoskeletal organization, formation of the sealing zone, and osteoclast activity (63, 76). 
Therefore, miR-31 promotes osteoclast formation and activity, and RhoA is a major 
mediator of its function. 
 
miR-155 
As regulators of skeletal homeostasis, miRNAs with a negative role in osteoclasts 
have also been identified. For example, pro-inflammatory signals, including TNFα and 
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Interferon β (IFN-β), activate the expression of miR-155 during monocytic differentiation 
and activation (59). miR-155 was shown to promote the commitment of monocyte 
precursors to the macrophage lineage, at the expense of osteoclastogenesis (58). In 
RAW264.7 cells, miR-155 over-expression impairs in vitro osteoclast formation and 
resorption activity after treatment with M-CSF and RANKL. In particular, over-
expression of miR-155 blocks the early stages of osteoclastogenesis, prior to fusion of the 
precursors into multinucleated cells (58). In contrast, expression a miR-155 sponge 
construct, which inhibits the function of miR-155, enhances osteoclast formation in 
mouse BMM cultures (59). 
The negative role of miR-155 on osteoclastogenesis is mediated by the repression 
of the transcription factor MITF. As discussed in the previous section, MITF induces the 
expression of key genes for osteoclast maturation and function: TRAP, OSCAR, and 
Cathepsin K (77). In osteoclasts, as well as in other myeloid cells, miR-155 also inhibits 
SOCS1 (suppressor of cytokine signaling 1), a protein that contributes to the signal 
transduction of cytokines, such as IFN-β (59). By repressing the negative effects of pro-
inflammatory cytokines on the differentiation of the progenitor cells, SOCS1 supports 
osteoclastogenesis (78). Based on these findings, miR-155 down-regulates genes that are 
important for the differentiation of the progenitor cells to osteoclastogenesis, therefore 
favoring the macrophage fate. 
Controversially, Blum and colleagues showed that, in an arthritis model, bone 
marrow precursors from miR-155-null mice have reduced osteoclast potential (60). 
Differences between this study and the in vitro findings by Zhang et al. suggest that miR-
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155 could play distinct roles in different phases of the multi-step process of 
osteoclastogenesis. Therefore, a negative function of miR-155 on the commitment of the 
precursors to the osteoclast lineage does not exclude its ability to support osteoclast 
terminal differentiation. Alternatively, global miR-155-null mice may have decreased 
osteoclast differentiation potential due to the effects of the miR-155-null mutation on 
cells of other lineages, such as immune cells and osteoblasts. 
 
miR-124 
Similarly, miR-124 blocks osteoclast differentiation, and one of its targets is a 
major pro-osteoclastogenic factor, NFATc1 (55). Activation of the osteoclastogenic 
program by RANKL down-regulates miR-124 in mouse BMMs. Accordingly, over-
expression of miR-124 inhibits osteoclast formation, whereas its knock-down promotes 
differentiation. Moreover, the proliferation and migration of the osteoclast precursors are 
diminished when miR-124 is over-expressed, suggesting that miR-124 regulates these 
important processes in osteoclasts (55). 
 
miR-146a 
Expression of miR-146a inhibits the RANKL- or TNFα-induced osteoclast 
differentiation of human PBMCs, as well as their bone resorption activity (56). miR-146a 
plays an important role in inflammation, and is up-regulated in activated macrophages 
(79). Additionally, in response to TNFα and IL-1β stimuli, NFκB drives miR-146 
expression, and miR-146, in turn, targets TRAF6 (Tumor necrosis factor receptor-
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associated factor 6) and IRAK1 (IL-1 receptor-associated kinase), in a negative feedback 
mechanism to limit NFκB signaling (80). TRAF6 is an ubiquitin ligase with a 
fundamental role in osteoclast maturation, and its targeting by miR-146a likely represents 
a key mechanism for repression of osteoclastogenesis. Further, in a mouse model of 
arthritis, systemic administration of a miR-146a mimic prevents joint destruction and 
bone erosion. This is achieved by reducing osteoclast number, providing an in vivo 
confirmation of the negative role of miR-146a on osteoclastogenesis (56).  
 
miRNAs and bone mass: miR-503 and miR-133 
 To correlate the function of specific miRNAs with the development of 
pathological conditions, modifications in the miRNA expression profile of osteoclast 
precursors have also been evaluated in selected cohorts of osteoporosis patients. For 
example, dramatic down-regulation of miR-503 was detected in CD14+ peripheral blood 
mononucleated cells (PBMCs) of post-menopausal osteoporosis patients (65). In vitro, 
inhibition of miR-503 induces osteoclast differentiation of CD14+ PBMCs from healthy 
subjects. Moreover, over-expression of miR-503 decreases osteoclast formation in 
PBMCs from osteoporosis patients (65). miR-503 was found to regulate bone mass 
through direct targeting of RANK (65). In vivo, administration of a miR-503 inhibitor 
increases osteoclast formation, decreases bone mineral density (BMD), and reduces bone 
resorption parameters, whereas systemic injection of a miR-503 mimic caused the 
opposite bone phenotype (65). These results confirm that miR-503 expression negatively 
impacts osteoclastogenesis. Further, the expression of miR-503 in osteoclasts is induced 
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by estrogen, and decreased in ovariectomized (OVX) mice (65). Overall, these 
observations suggest that miR-503 may play an important role in the development of 
post-menopausal osteoporosis. 
 In contrast to miR-503, the expression of miR-133a is increased in circulating 
monocytes from post-menopausal women with low bone mineral density (BMD). This 
suggests that miR-133a may be a potential monocytic biomarker for post-menopausal 
bone loss. However, the authors of this study failed to identify direct targets of miR-133a 
which could mediate its function in bone resorbing cells, although this miRNA has been 
investigated in osteoblasts and chondrocytes, where it targets Runx2 (81). 
 
Conclusions 
Bone homeostasis depends on the coupling of bone formation and resorption, 
during the process of remodeling. Osteoclast differentiation, function, and survival must 
be finely regulated to assure proper bone resorption activity. Understanding the molecular 
mechanisms that participate in the regulation of osteoclastogenesis and bone resorption is 
vital for the development of therapeutics for bone diseases characterized by alterations in 
the osteoclast compartment. 
Osteoblasts, osteocytes, and immune cells can regulate osteoclast differentiation 
and activity. This is achieved through the expression of cell surface molecules and the 
secretion of numerous soluble factors, including cytokines, hormones, growth factors, 
and the decoy receptor OPG. On the osteoclast, these factors can trigger complex 
intracellular signaling pathways, which converge in the activation of specific 
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transcription factors that promote the expression of genes important for osteoclast 
maturation and bone resorption. 
However, post-transcriptional mechanisms also play an important role in 
osteoclast differentiation and function, and miRNAs are key components of this process. 
Only few miRNAs and target genes have been identified in the osteoclast lineage, where 
they can modulate multiple aspects of osteoclast biology, including commitment and 
migration of the precursors, maturation, resorption, and survival of the osteoclasts. 
Clearly, additional studies are required to gain a more comprehensive knowledge of the 
function of miRNAs in osteoclastogenesis. 
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CHAPTER 2: 
 
SPECIFIC AIMS AND HYPOTHESES 
 
 The overall aim of the studies described in this dissertation is to improve our 
understanding of the basic mechanisms regulating the differentiation and function of 
osteoclasts. This work will describe the miRNA-mediated post-transcriptional regulation 
of key osteoclast genes, which could contribute to the development of novel therapeutic 
strategies for bone diseases characterized by alterations of bone resorption. 
 We hypothesize that specific miRNAs fine tune gene expression to regulate 
osteoclastogenesis, and, in particular, that: 1) miR-29 promotes osteoclast differentiation, 
and 2) miRNA profiling of differentiating osteoclast precursors will highlight novel 
miRNAs important for regulating osteoclast differentiation, and new genes and pathways 
that play a role in this process.  
 
Chapter 3: Specific Aim 1. To test the hypothesis that miR-29 promotes 
osteoclastogenesis. 
1a) To analyze the expression of the miR-29 family members during in vitro 
osteoclastogenesis, we will utilize quantitative RT-PCR and examine RNA from 
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differentiating cultures of mouse primary osteoclast precursors and of the monocytic cell 
line RAW264.7.  
1b) To investigate the function of miR-29 in the osteoclast lineage, we will analyze 
osteoclastogenesis, proliferation, migration, and survival of RAW264.7 cells stably 
transduced with a doxycycline-inducible construct for miR-29 knock-down (miR-29 
sponge). 
1c) To identify novel miR-29 targets in osteoclasts, we will use miRNA target prediction 
algorithms (DIANA-microT 3.0, PicTar, miRanda, or TargetScan), and validate potential 
miR-29 targets in the monocytic RAW264.7 cell line using Luciferase Reporter-UTR 
assays. 
 
Chapter 4: Specific Aim 2. To profile miRNA expression of differentiating osteoclast 
precursors, and identify novel potential regulators of osteoclast differentiation and 
function. 
2a) To investigate the expression of mature miRNAs during osteoclastogenesis, we will 
perform a miRNA microarray analysis on a bone marrow population enriched for 
osteoclast precursor cells. We will determine miRNA expression in the early, middle, and 
late stages of RANKL-driven osteoclastogenesis. Further, we will profile miRNA 
expression in osteoclast cultures differentiated for 3 days with M-CSF and RANKL and 
in undifferentiated cells cultured with M-CSF alone. The expression of selected miRNAs 
will be confirmed by qPCR. 
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2b) To identify genes and functional pathways that are potentially regulated by miRNAs 
in the osteoclast lineage, we will perform a computational pathway prediction study for 
differentially expressed miRNAs that were identified by the microarray analysis. 
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CHAPTER 3: 
miR-29 Promotes Murine Osteoclastogenesis by Regulating Osteoclast 
Commitment and Migration 
 
This work has been published: Franceschetti, T., Kessler, C.B., Lee, S.K., Delany, A.M. J 
Biol Chem. 2013;288(46):33347-60. 
 
CHAPTER ABSTRACT 
Osteoclast differentiation is regulated by transcriptional, post-transcriptional, and post-
translational mechanisms. microRNAs (miRNAs) are fundamental post-transcriptional 
regulators of gene expression. The function of the miR-29 (a/b/c) family in cells of the 
osteoclast lineage is not well understood. In primary cultures of mouse bone marrow-
derived macrophages, inhibition of miR-29a, -29b, or -29c diminished formation of 
tartrate-resistant acid phosphatase (TRAP)-positive multinucleated osteoclasts, and the 
osteoclasts were smaller. qRT-PCR showed that all miR-29 family members increased 
during osteoclast differentiation, in concert with mRNAs for the osteoclast markers Trap 
(Acp5) and Cathepsin K. Similar regulation was observed in the monocytic cell line 
RAW264.7. In stably transduced RAW264.7 cell lines expressing an inducible miR-29 
competitive inhibitor (sponge construct), miR-29 knock-down impaired osteoclastic 
commitment and migration of pre-osteoclasts. However, miR-29 knock-down did not 
affect cell viability, actin ring formation, or apoptosis in mature osteoclasts. To better 
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understand how miR-29 regulates osteoclast function, we validated miR-29 target genes 
using Luciferase-3’ UTR (untranslated region) reporter assays and specific miR-29 
inhibitors. We demonstrated that miR-29 negatively regulates RNAs critical for 
cytoskeletal organization, including Cell Division Control protein 42 (Cdc42) and SLIT-
ROBO Rho GTPase activating protein 2 (Srgap2). Moreover, miR-29 targets RNAs 
associated with the macrophage lineage: G protein-coupled receptor 85 (Gpr85), Nuclear 
Factor I/A (Nfia), and Cd93. In addition, Calcitonin receptor (Calcr), which regulates 
osteoclast survival and resorption, is a novel miR-29 target. Thus, miR-29 is a positive 
regulator of osteoclast formation, and targets RNAs important for cytoskeletal 
organization, commitment, and osteoclast function. We hypothesize that miR-29 controls 
the tempo and amplitude of osteoclast differentiation. 
 
INTRODUCTION 
 
Osteoclasts are the only cells able to resorb mineralized matrix. The activity of 
these cells is critical for bone growth, normal bone remodeling, and fracture repair. A 
fine balance between the number and activity of osteoblasts and osteoclasts is necessary 
for bone homeostasis (2). Pathologies associated with abnormal osteoclast number or 
function include osteopetrosis, osteoporosis, and inflammatory osteolysis. Osteopetrosis 
is caused by impaired resorption, due to insufficient osteoclast formation or activity, and 
results in augmented bone density. In this disorder, changes in bone morphology are 
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often accompanied by immunodeficiency and anemia, due to narrowing of the bone 
marrow cavity and reduced expansion of the hematopoietic cell populations (3, 4). 
Osteoporosis is caused by excessive bone resorption coupled with insufficient bone 
formation. Systemic loss of bone mass can be triggered and supported by hormonal 
imbalance, such as estrogen deficiency. In inflammatory osteolysis, signaling from 
immune cells in conditions such as rheumatoid arthritis and periodontal disease 
determine bone loss localized at the joints or in the oral cavity. Thus, abnormal 
osteoclastic activity can result in higher predisposition to fractures, impaired joint 
mechanics, and loss of teeth (5). 
The differentiation of osteoclasts from hematopoietic precursors is a complex 
multistep process (2). It begins with the commitment of multipotent precursors to 
differentiation along the osteoclast lineage. These committed monocytic cells 
subsequently migrate and fuse together to form multinucleated mature osteoclasts (82). 
Bone resorption is initiated when the osteoclast polarizes and organizes the cytoskeletal 
structures that form the sealing zone and ruffled border. These dynamic structures, which 
in vitro appear as an actin-rich ring, mediate the degradation of the bone surface, creating 
an acidic environment and secreting proteolytic enzymes, to degrade the inorganic and 
organic components of bone matrix, respectively (11). Tight control of the complex 
osteoclast differentiation process is accomplished by the regulation of gene expression at 
multiple transcriptional, post-transcriptional, and post-translational levels (83). 
Substantial progress has been made in describing the mechanisms of M-CSF and 
RANKL driven osteoclastogenesis and bone resorption, and key transcription factors 
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involved include c-Fos, NFATc1, and NFĸB. In addition, several studies highlight the 
role of post-translational modifications, mainly phosphorylation, in regulating the activity 
of receptors and kinases important for transducing intracellular signals, such as the M-
CSF receptor (c-Fms), Src, and c-Jun N-terminus kinase (JNK) (12, 83). However, in the 
last decade, the importance of an additional level of gene regulation has emerged: post-
transcriptional control by microRNAs (miRNAs). 
miRNAs are short sequences of non-coding, single-stranded RNA that can bind 
target messenger RNAs (mRNAs) based on sequence complementarity. This process 
involves the RNA-induced silencing complex (RISC), which, for the most part, mediates 
the inhibition of gene expression by decreasing translation and/or by decreasing mRNA 
stability (84). Often, miRNAs regulate biological functions by modulating the expression 
of multiple genes that participate in the same or correlated pathways (85). miRNA levels 
are rapidly altered during embryonic development, as well as in adulthood, resulting in 
prompt and efficient post-transcriptional control (8, 86). 
The overall importance of the miRNA processing pathway in the osteoclast 
lineage was reported. In vitro silencing of key factors involved in miRNA processing, 
including DiGeorge syndrome critical region 8 gene (DGCR8), Argonaute2 (Ago2), and 
Dicer1, suppressed osteoclast differentiation and activity (53). In vivo, deletion of Dicer 
in the monocyte/macrophage lineage, using a CD11b promoter driven-cre recombinase, 
as well as in mature osteoclasts using a Cathepsin K promoter driven-cre, resulted in the 
development of a mild osteopetrotic phenotype (53, 54). 
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Recent studies identified specific miRNAs and miRNA targets involved in 
osteoclast commitment and differentiation. For example, miR-223 promotes osteoclast 
formation, at least in part, through the inhibition of NFIA (Nuclear factor 1/A) (53, 61). 
Decreased NFIA expression is necessary for the terminal differentiation of osteoclasts 
(53), as well as granulocytes and monocytes (68, 69). Further, miR-21 promotes 
osteoclast differentiation, and it was shown to target PDCD4 (programmed cell death 
domain 4). PDCD4 represses activator protein 1 (AP-1)-dependent transcription, and the 
AP-1 family member c-Fos is essential for osteoclastogenesis (83). Therefore, by 
suppressing AP-1 function, PDCD4 may exert a negative effect on osteoclast 
differentiation. Another report demonstrated a negative effect of miR-155 on 
osteoclastogenesis. miR-155 promotes the commitment of progenitor cells to the 
macrophage lineage, through repression of MITF (microphthalmia-associated 
transcription factor) (58). MITF is required in the later phases of osteoclast formation, 
where it promotes the expression of genes crucial for osteoclast maturation and function, 
like Trap, Oscar (osteoclast-associated immunoglobulin-like receptor), and Cathepsin K 
(77). 
We and others have studied the role of the miR-29 family in cells of the osteoblast 
lineage. Although miR-29 family members target several critical extracellular matrix 
mRNAs and limit their expression, this miRNA family promotes osteoblastic 
differentiation, by targeting negative regulators of this process (87-89). We considered 
that miR-29 family members may also play a role in osteoclastogenesis, given that altered 
miR-29 levels were associated with hematopoietic malignancies. For example, 
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diminished miR-29 levels were found in patients with chronic lymphocytic leukemia 
(CLL), and correlate with advanced clinical features and poor prognosis in acute myeloid 
leukemia (AML) (90-93). 
In this study, we characterized the expression of miR-29 family members during 
the differentiation of murine bone marrow-derived osteoclast cultures and an osteoclast 
precursor cell line. We show that miR-29 is important for cell migration, osteoclast 
commitment and differentiation, and we identified 6 novel miR-29 targets in osteoclastic 
cells. 
 
MATERIALS AND METHODS 
 
Cell Culture. 
Primary osteoclast precursor cultures were established from bone marrow of 6-8 
week old C57BL/6 male mice, which had been depleted of B220/CD45R-positive and 
CD3-positive cells (B and T lymphocytes, respectively). Briefly, bone marrow was 
isolated from femurs, tibias, and humeri (94). Cells were incubated with Phycoerythrin 
(PE)-conjugated primary antibodies for B220 and CD3 (eBioscience, San Diego, CA), 
and with magnetically labeled anti-PE microbeads (Miltenyi Biotec, Auburn, CA). 
Magnetic-Activated Cell Sorting (MACS®) Column Technology (Miltenyi Biotec, 
Auburn, CA) was used to capture CD45R and CD3 positive cells in the column, and the  
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flow-through contained a 
population of cells enriched for the 
monocytic and non-lymphoid lineage 
cells (43). Flow cytometric analysis 
confirmed that this procedure 
depleted 93-95% of T and B cells, 
thereby decreasing the heterogeneity of 
the marrow cells that were subsequently 
plated for experiments (Figure 3.1). 
Cells were cultured in α-MEM (Gibco 
Life Technologies, Grand Island, NY) 
supplemented with 10% FBS (Fetal 
Bovine Serum, Atlas Biologicals, Fort 
Collins, CO) and 30 ng/ml murine recombinant Macrophage Colony-Stimulating Factor 
(M-CSF) (eBioscience, San Diego, CA). Bone marrow-derived osteoclast precursor cells 
were plated in the presence of 30 ng/ml murine recombinant M-CSF and Receptor 
activator of nuclear factor kappa-B ligand (RANKL) (eBioscience) for up to 5 days. 
The mouse monocytic RAW264.7 (RAW) cell line was obtained from American 
Type Culture Collection (ATCC, Manassas, VA) (TIB-71TM), and cultured in DMEM 
(Gibco Life Technologies, Grand Island, NY) supplemented with 10% FBS. Cells were 
cultured in α-MEM supplemented with 10% FBS and 30 ng/ml RANKL, to stimulate 
osteoclastic differentiation. 
 
Figure 3.1. Flow cytometric analysis of the 
MACS sorted bone marrow cells. 
Expression of the lymphocyte-specific 
surface antigens CD45R and CD3 was 
evaluated by flow cytometry. SSC (side 
scattered light) is a measure of cell internal 
complexity. Percentage of CD45R/CD3+ 
cells in the total population is indicated. 
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The human embryonic kidney (HEK293T) PhoenixTM-Eco cell line was a gift 
from Nolan Lab, Stanford University, CA (95), and used for retrovirus production. These 
cells were cultured in DMEM supplemented with 10% FBS. The HEK293FT cell line 
was obtained from Invitrogen (Life Technologies, Grand Island, NY) and used for 
lentivirus production. 293FT cells were cultured in DMEM supplemented with 10% FBS.  
 
In Vitro Osteoclast Formation Assay. 
Cells were fixed in 2.5% glutaraldehyde in PBS, and TRAP activity was detected 
according to the manufacturer’s instructions, using the Acid Phosphatase Leukocyte 
(TRAP) kit (Sigma-Aldrich). TRAP positive multinucleated cells containing more than 
three nuclei were counted as osteoclasts under microscopic examination. Osteoclast area 
was quantified using cellSens imaging software (Olympus, Center Valley, PA). 
 
Quantitative Real time PCR. 
Primary osteoclast precursors and RAW264.7 cells were plated at 53,000 
cells/cm2. Total RNA was isolated from differentiating cultures using the miRNeasy Mini 
kit (Qiagen, Valencia, CA). On-column DNase treatment was performed to reduce 
contamination with genomic DNA, and an additional treatment with RQ1 DNase 
(Promega, Madison, WI) was performed prior to gene expression analysis. miR-29 
expression levels were analyzed with the TaqMan MicroRNA Assay (Life Technologies, 
Grand Island, NY). According to the manufacturer’s instructions, 22.5 ng of RNA were  
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reverse transcribed with specific 
primers to generate cDNA. miR-
29 expression was detected by 
qPCR in a MiQqPCR cycler (Bio-
Rad) and normalized to U6 small 
nuclear RNA (RNUB6) levels 
using the absolute quantification 
method. 
 To quantify mRNA levels 
in total RNA, DNased RNA was 
reverse-transcribed using Moloney 
murine leukemia virus-reverse 
transcriptase (Invitrogen), and 
quantified by qPCR with iQ SYBR 
Green Supermix (Bio-Rad). The 
primer sets used are shown in 
Table 3.1. RNA levels were 
determined using absolute quantification and normalized to hypoxanthine-guanine 
phosphoribosyltransferase (HPRT) mRNA. RNA experiments were performed at least 
twice, and each experiment contained biological triplicates. For qRT-PCR, each sample 
was analyzed in duplicate. 
 
Table 3.1. Primer sets for gene expression 
analysis. The sequences of the primers used for 
quantitative RT-PCR analysis are reported [primers 
for HPRT, Cathepsin K, and TRAP as indicated in 
(96)] 
PRIMER NAME SEQUENCE (5’ – 3’) 
HPRT FW gttggatatgcccttgactataatga 
HPRT RV caacatcaacaggactcctcgtatt 
Cathepsin K FW cgaaaagagcctagcgaaca 
Cathepsin K RV tgggtagcagcagaaacttg 
TRAP FW cgtctctgcacagattgcat 
TRAP RV aagcgcaaacggtagtaagg 
GFP FW gtgagcaagggcgaggagctgttc 
GFP RV gtaggtcagggtggtcacgaggg 
F4/80 FW tttcctcgcctgcttcttc 
F4/80 RV ccccgtctctgtattcaacc 
Mac-1 FW tcctgtttaatgactctgcgttt 
Mac-1 RV ggctccactttggtctctgt 
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Retroviral Constructs. 
 To obtain miR-29 knock-down, double-stranded oligonucleotides targeting the 
miR-29a precursor were cloned into the retroviral vector pSilencer 5.1-H1 Retro 
(Ambion). The sequences of the oligonucleotides used are indicated in Table 3.2. The 
silencing construct was inserted into the pSilencer vector using BamHI and HindIII 
restriction enzymes. As negative control, pSilencer 5.1 Retro Scrambled was used 
(Ambion). Retrovirus was produced using the HEK293TPhoenixTM-Eco cell line (95). 
 
miR-29 Knock-down and Osteoclast Formation. 
 Whole bone marrow was isolated from 6-8 week old C57BL/6 mice and plated 
overnight on a tissue culture plastic plate to limit the amount of stromal cells. The non-
adherent population of cells was centrifuged on a Ficoll gradient, to enrich for 
macrophage precursors (97). These bone marrow-derived macrophages (BMMs) were 
seeded at 5,000 cells/well in 96-well plates, in α-MEM supplemented with 10% FBS in 
the presence of 30 ng/ml M-CSF. 48 hours after plating, cells were transfected with 50 
nM anti-miRNA inhibitors (Dharmacon) using BioT reagent (Bioland Scientific, 
Paramount, CA). Alternatively, cells were transduced with retroviruses harboring a miR-
29a knock-down construct or a scrambled control. Osteoclast differentiation was induced 
with RANKL treatment (10 ng/ml), and osteoclast formation was evaluated by TRAP 
staining. 
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pSLIK Lentiviral Constructs. 
 To knock-down the activity of all miR-29 family members, we generated a miR-
29 “sponge”, which works as a competitive target for miR-29, relieving the repression of 
its endogenous target mRNAs (Figure 3.5) (98). The murine osteonectin 3’ UTR contains 
Table 3.2. PCR cloning primers. GenBank reference numbers for the genes of interest 
are indicated. Restriction sites are underlined. MluI (FW) and HindIII (RV) restriction 
enzymes were used for all the genes, with the exception of Cdc42-UTR, for which SacI 
and MluI were used. In the oligonucleotides for miR-29 knock-down construct, BamHI 
and HindIII sites are indicated. 
RNA (MOUSE) FW PRIMER (5’ – 3’) RV PRIMER (5’ – 3’) 
Calcr 
(NM_007588.2) 
ggatacgcgtatgtgaagccaccccaagca
ttgtgatcc 
cggcaagcttcatgtacacagcagaagcgtttcaca
c 
Trap 
(NM_001102405.1) 
tctacgcgtagatggattcatgggtggtg tttaagcttctggaacctcttgtcgctggc 
Cathepsin K 
(NM_007802.3) 
tttacgcgtattccagccagccagcccatc 
cgggccaagcttaaattgtaaatgagatactttatttca
aatacaaag 
Srgap2 
(NM_001081011.2) 
tttacgcgtctgccctacatcctctctcc tttaagcttaagggcatggtggtgcatgcttttaatttc 
Cdc42-CDS 
(NM_009861) 
tctacgcgtgacaagatctaatttgaaatatta
aaag 
tctaagcttagttggtacatattccgatggg 
Cdc42-UTR 
(NM_009861) 
tttgagctcaaaggcctaaagaatgtgaaac tctacgcgtcatatacaaagagttgagacac 
Gpr85 
(NM_145066.4) 
tttacgcgttgaggcgctgtttcagcac cccaagcttcacataatacagttcaatgctagc 
Cd93 
(NM_010740.3) 
tttacgcgttgtcccttaaacttgcaaaag tttaagcttccttcccagaggcttactcg 
Nfia 
(NM_010905.3) 
tttacgcgtaccatcctccagacagacca cccaagcttcaggtgttgccatacatgtgt 
miR-29a 
knock-down 
gatccgttcagagtcaatagaattctcaaga
gaaattctattgactctgaacttttttggaaa 
agcttttccaaaaaagttcagagtcaatagaatttctct
tgagaattctattgactctgaacg 
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a pair of miR-29 binding sites, within cDNA bases 1083 to 1149. 3 copies of this tandem 
miR-29 binding site were cloned downstream of a GFP reporter gene, to generate the 
miR-29 sponge. The GFP alone control or GFP_Sponge cDNAs were subcloned in the 
pEN_Tmcs entry vector [plasmid 25751, Addgene, Cambridge, MA; (99)], which 
contains a tetracycline inducible promoter (tetracycline responsive element, TRE). These 
constructs were subjected to Gateway recombination with the lentiviral construct pSLIK, 
harboring a hygromycin resistance selectable marker gene [plasmid 25737, Addgene; 
(99)]. The Ubi-C (ubiquitin C) promoter in the pSLIK vector constitutively drives the 
expression of the tetracycline activator (rtTA3), which, in the presence of doxycycline 
(DOX), promotes the expression of the GFP or GFP_Sponge transgene from the TRE 
promoter. 
 
Lentivirus Production and Transduction. 
 pSLIK constructs containing GFP alone or GFP_Sponge genes were co-
transfected in the HEK293FT cell line, along with the expression vectors for the viral 
packaging proteins. These include the viral trans-activators Tat (pHDM-tat1b) and Rev 
(pRC/CMV-rev1b), the viral core polyprotein and reverse transcriptase, encoded by the 
GAG and POL genes respectively (pHDM-Hgpm2), and the VSV-G (vesicular stomatitis 
virus) envelope glycoprotein (pHDM-G) (gift from the Lee lab, Harvard Gene Therapy 
Initiative, MA). Culture medium containing the lentiviral particles was used to transduce 
RAW264.7 cells. Pools of stably transduced cells were established by culture in the 
presence of hygromycin (100 µg/ml). 
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miR-29 Sponge Expression and Osteoclast Differentiation. 
 GFP and GFP_Sponge RAW264.7 cell lines were seeded at a cell density of 
1,000 cells/well in 96-well plates, in DMEM supplemented with 10% FBS. 24 hours 
later, osteoclast differentiation was stimulated by treatment with 30 ng/ml RANKL in α-
MEM supplemented with 10% FBS. The expression of the transgene was induced by 
addition of 500 ng/ml doxycycline (DOX) to the culture medium (Sigma-Aldrich). 
Osteoclast formation was evaluated by TRAP staining. 
 
Cell Viability Assay. 
 GFP and GFP_Sponge RAW264.7 cells were plated in 96-well plates at 5,000 
cells/well, in DMEM supplemented with 10% FBS. 24 hours later, cells were treated with 
30 ng/ml RANKL, to induce osteoclastogenesis, in the presence or absence of 500 ng/ml 
doxycycline, to activate transgene expression. Cell viability was assessed over 3 days by 
MTS assay using the CellTiter 96 AQueous One Solution Cell Proliferation Assay kit, as 
indicated by the manufacturer’s instructions (Promega). 
 
Phagocytosis Assay. 
 GFP and GFP_Sponge RAW264.7 cells were cultured in α-MEM supplemented 
with 10% FBS in the presence of 500 ng/ml of doxycycline and 30 ng/ml of RANKL for 
24 hours prior to the assay. Cells were then plated at 100,000 cells/well in 96-well plates, 
and allowed to adhere to the plate for 3 hours. Culture medium was replaced with a 
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solution of pHrodo S. aureus bacterial particles (250 µg/ml), which will emit 
fluorescence when phagocytosed (Life Technologies). Cells were incubated for 1 hour at 
37ºC, and nuclei were stained with DAPI. Cultures were analyzed by fluorescence 
microscopy. Phagocyotosis of pHrodo particles was quantified by measuring 
fluorescence emitted at 590 nm, and normalized to DAPI fluorescence at 460 nm. 
  
Macrophage Commitment Assay. 
 GFP and GFP_Sponge RAW264.7 cells were plated at 26,000 cells/cm2 in 
DMEM supplemented with 10% FBS. Subsequently, cells were cultured in α-MEM 
supplemented with 10% FBS in the presence of 500 ng/ml of doxycycline and 30 ng/ml 
of RANKL for 24 hours. Total RNA was isolated from the cultures using the miRNeasy 
Mini kit (Qiagen, Valencia, CA), and the expression of macrophage marker genes was 
analyzed by qPCR as previously described. The primer sets used are shown in 
Supplemental Table S1. 
 
Cell Migration Assay. 
 GFP and GFP_Sponge RAW264.7 cells were cultured in DMEM, in the absence 
of FBS, and in the presence of 500 ng/ml of DOX for 24 hours prior to the assay. Cells 
were then plated at 200,000 cells/well on 8 µm pore polycarbonate membrane inserts in 
6.5 mm Transwells (Corning, Tewksbury, MA). 30 ng/ml M-CSF was added to the 
bottom chamber, as a chemotactic agent. Cells were incubated overnight, in the presence 
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of DOX. Cells that did not migrate were removed from the top side of the transwell 
membrane using a cotton swab. Upon fixation with 3.7% formaldehyde, cells on the 
bottom side of the transwell membrane were stained with 0.05% Crystal violet solution. 
Crystal violet stain was solubilized using 100% methanol, and optical density was 
quantified at 540 nm. 
 
Apoptosis Assay. 
 GFP and GFP_Sponge RAW264.7 were plated at 3,125 cells/cm2 in DMEM 
supplemented with 10% FBS. 24 hours later, culture medium was switched to α-MEM 
supplemented with 10% FBS, with the addition of 30 ng/ml of RANKL. After 2 days of 
differentiation, expression of the transgene was induced with 500 ng/ml of DOX. 2 days 
later, osteoclast apoptosis was assessed by Caspase-3 Colorimetric Assay Kit, as 
indicated by the manufacturer’s instructions (GenScript, Piscataway, NJ). 
 
Actin Ring Formation Assay. 
 GFP and GFP_Sponge RAW264.7 cells were seeded on glass chamber slides at 
3,125 cells/cm2, in DMEM supplemented with 10% FBS. 24 hours later, culture medium 
was switched to α-MEM supplemented with 10% FBS, with the addition of 30 ng/ml of 
RANKL and 500 ng/ml of doxycycline. End point cultures were fixed with 3.7% 
formaldehyde and F-actin was labeled with Rhodamine Phalloidin conjugate (Life 
Technologies). Nuclei were visualized by using mounting medium containing DAPI 
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(4',6-Diamidino-2-Phenylindole) (Invitrogen, Life Technologies). Cultures were analyzed 
by fluorescent microscopy. 
  
Luciferase Constructs. 
 Gene-specific PCR primers were used to amplify from mouse genomic DNA 
template the coding sequences (CDS) or untranslated regions (UTRs) for Calcitonin 
Receptor, Tartrate resistant acid phosphatase (Trap), Cathepsin K, Cdc42, Srgap2, 
Gpr85, Cd93, and Nfia, which contained potential miR-29 binding sites (primer 
sequences are reported in Table 3.2). Using the appropriate restriction enzymes, these 
fragments were cloned downstream from Luciferase, in the Cytomegalovirus promoter-
driven Luciferase 
reporter vector 
pMIR-REPORT 
(Ambion, Austin, 
TX). Site-directed 
mutagenesis, to 
delete putative miR-
29 binding sites in 
selected constructs, 
was performed by 
overlap extension 
Table 3.3. Primer sets for site-directed mutagenesis of miR-
29 targets. Forward primers were designed to delete miR-29 
binding sites (see Table 3.4), and used in combination with 
complementary reverse primers. 
RNA (MOUSE) FW MUTAGENESIS PRIMER (5’ – 3’) 
Calcr (site 2565) gtttataaagcagatctagcagtaagagaa 
Cdc42-CDS aattaagtgtgttgttggtaaaacatgtct 
Srgap2 ccccagctctgggagctgacgcctgtgaga 
Gpr85 gtgggtgaacactagagtatcagtgctaaa 
Cd93 (site 4403) agccaatggagccactattttcacatatat 
Nfia (site 2125) ttttaatactttagggaaatggttgggctg 
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(primer sequences are reported in Table 3.3). Luciferase plasmids containing the regions 
of interest were used as templates for mutagenesis. All constructs were verified by 
sequencing. 
 
Luciferase Activity Assay. 
RAW264.7 cells were plated at 58,000 cells/cm2. After 24 hours, cells were co-
transfected with Luciferase constructs and a constitutively expressing β-Galactosidase 
construct, as a control vector for transfection efficiency (GenBank accession number 
U02451) (Clontech, Mountain View, CA) using BioT (BioT:DNA ratio 1.5 μl:1 μg). In 
selected experiments, 50 nM anti-miR-29-a or -c or negative control (scrambled) miRNA 
inhibitors were also transfected. 6 hours post-transfection, cells were treated with or 
without RANKL (30 ng/ml) in α-MEM supplemented with 10% FBS. Following 48 
hours, cell lysates were harvested using Reporter Lysis Buffer (Promega). Samples were 
analyzed for Luciferase activity using Luciferase Assay System (Promega), and 
normalized to β-Galactosidase activity, which was assessed using Galacton® reagent 
(Applied Biosystem, Foster City, CA). Each Luciferase experiment was performed at 
least three times, using n=6. 
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Table 3.4. Potential miR-29 binding sites in genes important for the 
macrophage/osteoclast lineage. Putative miR-29 sites were identified using miRanda, 
DIANA-mirExTra, PicTar, and RNAhybrid. miR-29 family members have identical seed 
binding (miRNA bases 2-8), and the sequence for miR-29a is shown in the table. The 
position of the miR-29 site in the target mRNA sequence is indicated. The miR-29 sites 
mutated using the primers reported in Table 3.3 are indicated (±). 
RNA miR-29 site Sequence 
Calcr 2095 
3' UUGGCUAAAGUCUA----CCACGAU 5’  miRNA 
   :||| | |||||||    |||||| 
5' GACCUAGUUCAGAUACAGGGUGCUCC 3’ RNA 
Calcr 2565(±) 
3' UUGGCUAAAGUCUA-CCACGAU 5’     miRNA 
    |||  || |   | ||||||| 
5' UACCUCUUGCCCUUGGGUGCUAU 3’    RNA 
Trap 133 
3’ AUUGGCUAAAGU--CUACCACGAU 5’   miRNA 
     |  ||| |||    ||||||| 
5’ AGAUGGAU-UCAUGGGUGGUGCUGC  3’ RNA 
Ctsk 9764 
3' AUUGGCUAAAGUCUACCACGAU 5’ miRNA 
          | || | ||||||| 
5' UUUCUCCUCUC-GUUGGUGCUU 3’ RNA 
Cdc42 166(±) 
3' AUUGGCUAAAGUCUACCACGAU 5'  miRNA 
     :  |:|    |||||||||: 
5'  UGUUGGU----GAUGGUGCUGU 3' RNA 
Cdc42 683 
3' AUUGGCUAAA-------GUCUAC-CACGAU 5'  miRNA 
    ||||||          |||:|| |||||: 
5' GAACCGAAGAAGAGCCGCAGGUGUGUGCUGC 3' RNA 
Cdc42 1281 
3' AUUGGCUAAAGUCUACCACGAU 5' miRNA 
    |   |    ||  ||||||| 
5' AACGUGUCCCCACCUGGUGCUC 3' RNA 
Cdc42 1686 
3' UUGG-CUA--------AAG------UCUACCACGAU 5' miRNA 
   :||| |:|        |||      :|||||||:|| 
5' GACCUGGUACCUAGGGUUCCUAACGGGAUGGUGUUA 3' RNA 
Srgap2 6093(±) 
3’     UGGCUAAAGUCU-----ACCACGAU 5’ miRNA 
        | |  |||        ||||||| 
5’ CCUAGCUGUCUUCCUUAUCUCUGGUGCUU 3’ RNA 
Gpr85 2498(±) 
3' AUUGGCUAAAGUCUACCACGAU 5' miRNA 
     | |||    ||  ||||||| 
5' AUAACGAAAGUAGCAGGUGCUA 3' RNA 
Cd93 2421 
3' AUUGGCUAAAGUCUACCACGAU 5' miRNA 
     |  || ||   |||||||||  
5' CGAAGGAGUU--ACUGGUGCUA 3'RNA 
Cd93 4403(±) 
3' AUUGGCUAAAGUCUA-CCACGAU 5' miRNA 
   | ||:| |  :| || ||||||  
5' UCACUGUUCCUAAAUGGGUGCUU 3' RNA 
Cd93 5279 
3' AUUGGCUAAAGUCUACCACGAU 5' miRNA 
   | | |     |  | |||||||  
5' UCAUCACCAGCUCAGGGUGCUA 3' RNA 
Nfia 2125(±) 
3’  UGGC-----UAAAGUCUACCACGAU 5’ miR-29 
    ||:|     |||||  ||||||||: 
5’ GACUGUCGUAAUUUCUCAUGGUGCUG 3’ RNA 
Nfia 3056 
3’ UGGCUAAAGUCUACCACGAU 5’ miRNA 
          ||  |||||||| 
5’       AUCUAAUGGUGCUU 3’ RNA 
Nfia 7184 
3’  UGGC-----UAAAGUCUACCACGAU 5’ miRNA 
    ||:|     |||||  ||||||||: 
5’ GACUGUCGUAAUUUCUCAUGGUGCUG 3’ RNA 
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Data Analysis. 
 Data are presented as mean ± SEM. Data were analyzed by Student’s t test or 
one-way ANOVA with Bonferroni post-hoc test as appropriate (KaleidaGraph, Synergy 
Software, Reading, PA.
 
RESULTS 
 
miR-29 expression increases during in vitro osteoclast differentiation. 
We analyzed the expression of miR-29 family members in mouse bone marrow 
depleted of B220 and CD3 positive cells, and cultured in the presence of M-CSF and 
RANKL for up to 5 days. In these cultures, osteoclasts were evident by day 3, and 
osteoclast number and size where highest at day 5 (Figure 3.2B, C, and D). qRT-PCR 
showed that all the miR-29 family members, miR-29a, -b, and -c, were expressed at a 
similar level, and that their expression was not increased until between days 3 and 5 of 
differentiation (Figure 3.2A). In contrast, mRNA levels for the osteoclast markers TRAP 
and Cathepsin K were increased from day 1 to day 3, and sustained at day 5 (Figure 
3.2E). RANK expression was already elevated at day 1, and maintained during the course 
of osteoclast differentiation, whereas NFATc1 levels peaked at day 3, and then decreased 
(Figure 3.2F). 
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Figure 3.2. miR-29 increases during osteoclast differentiation in vitro. Primary 
bone marrow osteoclast precursors depleted of B and T cells were differentiated by 
culturing with 30 ng/ml, each, M-CSF and RANKL. A, miR-29a, -b, and -c expression 
was quantified after 1, 3, and 5 days of culture and normalized to U6 (n=4). B, Number 
of TRAP(+) osteoclasts per well (n=3, 96 well plate). C, Osteoclast area: boxplot lines 
represent the 25% quartile of the data, the median, and the 75% quartile. Outliers are 
denoted by dots. (n=3 wells, 96 well plate). D, Representative images of TRAP stained 
cultures after 1, 3, and 5 days of differentiation were captured using 10X magnification. 
E, F, Osteoclast marker mRNAs were quantified by qRT-PCR and normalized to 
HPRT (n=4). * significantly different from day 1, p<0.05. 
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miR-29 is a positive regulator of osteoclastogenesis.  
To investigate the role of miR-29 in osteoclast differentiation, we inhibited miR-
29 activity in primary cultures of bone marrow-derived macrophage/osteoclast precursors 
(BMMs), using transiently transfected miR-29a, -b, or -c specific oligonucleotide 
inhibitors. Throughout the time course analyzed, miR-29 inhibition resulted in a 
significant reduction in the number of TRAP positive multinucleated osteoclasts 
compared to the scrambled, non-targeting control (Table 3.5; Figure 3.3A). These data 
suggest that miR-29 inhibition does not merely delay osteoclastogenesis, and that miR-29 
activity is important for osteoclast formation. Consistent with these data, primary bone 
Table 3.5. miR-29 knock-down decreases osteoclast formation in vitro. Mature 
sequence of the non-targeting scrambled control (cel-miR-67) and the miR-29 family 
members is indicated. Divergent bases are underlined. Seed binding region (bases 2-8) is 
in italic. Primary BMMs were transfected with 50 nM anti-miR-29a, -b, or -c inhibitor or 
non-targeting scrambled control oligonucleotides. Cells were treated for 3 to 6 days with 
M-CSF (30 ng/ml) and RANKL (10 ng/ml). Osteoclast formation was evaluated by 
TRAP staining (n=4 wells, 96 well plate). * significantly different from 29a, -b, or -c 
inhibitor, p<0.01. 
Inhibitor Mature miRNA sequence Day 3 Day 4 Day 5 Day 6 
Scrambled ucacaaccuccuagaaagaguaga 5.2 ± 1.6* 21.6 ± 6.3* 46.0 ± 4.3* 203.8 ± 17.9* 
miR-29a uagcaccaucugaaaucgguua 0 0 11.0 ± 1.7 17.3 ± 1.4 
miR-29b uagcaccauuugaaaucgguua 0.7 ± 0.5 2.8 ± 1.0 10.2 ± 1.9 17.8 ± 1.9 
miR-29c uagcaccauuugaaaucaguguu 0 0 6.5 ± 2.3 17.8 ± 2.1 
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marrow-derived precursors transduced with a retrovirus expressing a miR-29a inhibitor 
also showed decreased osteoclast formation compared with control (Figure 3.3B). 
miR-29 family members have identical seed binding regions (miRNA bases 2-8). 
miR-29a and -29c differ by only one base, whereas miR-29b is more divergent. In the 
transient transfection studies shown in Table 1, the miR-29b inhibitor appeared to be 
somewhat less efficacious at the early time points, days 3 and 4. However, the isoform-
specific inhibitors had similar effects at the later time points, days 5 and 6. Overall, the 
miR-29 isoform inhibitors had similar activity. Given the degree of conservation among 
the miR-29 isoforms, it may be difficult to tease out isoform-specific effects using an 
inhibitor strategy.  
When BMMs were plated at a higher density, the formation of large osteoclasts 
(>8 nuclei) was significantly diminished in cells transiently transfected with miR-29c 
inhibitor [large osteoclast number (per well) in scrambled 108±5 versus miR-29a 
inhibitor 74±3, p<0.01]. This indicates that miR-29 knock-down negatively affects 
osteoclast size, suggesting that miR-29 activity plays a positive role in osteoclast 
maturation (Figure 3.3). 
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The primary 
cultures obtained from 
bone marrow are 
heterogeneous, even when 
depleted of lymphocytes 
(97). For this reason, we 
sought a more simplified 
and homogeneous model 
system for the purpose of 
evaluating the mechanisms 
by which miR-29 regulates 
osteoclast differentiation. 
Therefore, we chose to use 
the monocytic cell line 
RAW264.7. We first 
characterized the 
expression of miR-29 
family members in these 
cells after treatment with 
RANKL for up to 4 days. 
We found that expression 
of all miR-29 family  
 
Figure 3.3. Inhibition of miR-29 represses osteoclast 
formation in vitro. A, BMMs were transiently transfected 
with a miR-29a inhibitor and differentiated for 3 days with 
M-CSF (30 ng/ml) and RANKL (10 ng/ml). 
Representative images of the cultures were captured using 
10X magnification. B, BMMs were transduced with 
pSilencer retrovirus for miR-29a knock-down or a non-
targeting scrambled control, and differentiated for 3 days. 
Osteoclast formation was evaluated by TRAP staining 
(n=6 wells, 96 well plate). * significantly different from 
scrambled, p<0.05. 
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Figure 3.4. miR-29 expression in RAW264.7 cells recapitulates the pattern 
observed in primary osteoclast precursor cells. A, The expression of miR-29a, -b, 
and -c was analyzed over 4 days of differentiation with RANKL (30 ng/ml). B, Number 
of osteoclasts per well (n=3, 96 well plate). C, Osteoclast area: boxplot lines represent 
the 25% quartile of the data, the median, and the 75% quartile. Outliers are denoted by 
dots. (n=3 wells, 96 well plate). D, Representative images of TRAP stained cultures at 
days 0, 1, 2, 3, and 4 of differentiation, respectively, were captured using 10X 
magnification. E, F, Gene expression levels for osteoclast markers. * significantly 
different from day 0, p<0.05. 
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members was modestly, but significantly decreased after 24 hours of RANKL treatment 
(Figure 3.4A). Levels of miR-29a, -b, and -c then increased as osteoclastogenesis 
progressed, in a trend similar to that observed in the primary cultures (compare with 
Figure 3.2A). In these cultures, osteoclast number and size peaked on day 3, and were 
decreased on day 4 due to apoptosis of mature osteoclasts (Figure 3.4B-D). As observed 
in the primary cells, the osteoclast marker genes, Trap and Cathepsin K, also increased 
with osteoclastic differentiation (Figure 3.4E). In contrast, RANK was highly expressed 
throughout the time course analyzed, and NFATc1 increased at day 1 of RANKL-
treatment and was subsequently down-regulated (Figure 3.4F). These data suggested that 
RAW264.7 cells could be a valid surrogate for analyzing the mechanisms by which miR-
29 regulates osteoclastogenesis. 
 
Inhibition of miR-29 activity impairs osteoclastic differentiation of RAW264.7.  
To further define the activity of miR-29 in osteoclastogenesis, we developed an 
inducible lentiviral knock-down construct, based on the miRNA “sponge” strategy (98). 
The miR-29 sponge consisted of 6 miR-29 binding sites cloned downstream of GFP, in a 
DOX-inducible lentiviral vector (Figure 3.5A). Expression of the GFP_Sponge RNA can 
work as a decoy or competitive inhibitor for all the members of the miR-29 family, which 
share sequence identity in the seed region (nucleotides 2-8 of the miRNA sequence). 
RAW264.7 cells were stably transduced with lentivirus harboring the miR-29 “sponge” 
(GFP_Sponge cells) or GFP alone (GFP cells). 
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To confirm DOX-inducible expression of the transgene, we quantified GFP 
mRNA levels in GFP cells treated for 24 hours with different doses of DOX. qRT-PCR 
verified that GFP RNA was induced in a dose-responsive fashion, in the presence of 
increasing concentrations of DOX (Figure 3.5B). The 500 ng/ml dose of doxycycline was 
chosen for the subsequent assays because it produced a level of transgene expression 
 
Figure 3.5. miR-29 knock-down inhibits osteoclastic differentiation of RAW264.7 
cells. A, Schematic representation of doxycycline (DOX)-inducible GFP and 
GFP_Sponge constructs. TRE, tetracycline responsive element. B, GFP RAW264.7 cell 
line was treated for 24 hours with increasing concentrations of DOX. GFP mRNA 
expression was quantified by qRT-PCR and normalized to HPRT. C, GFP and 
GFP_Sponge RAW264.7 cells were treated with 500 ng/ml of DOX. After 2 and 3 days 
of differentiation with RANKL (30 ng/ml), osteoclast formation was evaluated by 
TRAP staining (n=6, 96 well plate). * significantly different from GFP, p<0.05. 
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similar to that of TRAP mRNA, while representing a DOX dose well below that recently 
reported to decrease osteoclast differentiation in bone marrow cells in vitro (100). 
We used the GFP_Sponge RAW264.7 cells as a relatively homogeneous cell 
population to study the mechanisms by which miR-29 regulates osteoclastogenesis. In 
cells treated with DOX and RANKL, we observed reduced formation of TRAP-positive 
multinucleated cells in the GFP_Sponge 
cultures after 2 days, in comparison with the 
cells expressing the GFP transgene only 
(Figure 3.5C). After 3 days, this disparity 
was even more pronounced, as the formation 
of TRAP-positive multinucleated cells was 
increased only in the GFP RAW264.7 
cultures. There was no difference in the 
ability of GFP and GFP_Sponge cells to 
form TRAP-positive multinucleated cells in 
the absence of DOX (data not shown). These 
results confirm the positive role of miR-29 in 
osteoclastogenesis, as observed in primary 
cells (Table 3.5; Figure 3.3). 
To determine whether miR-29 knock-
down in the GFP_Sponge cultures impaired 
 
Figure 3.6. Inhibition of miR-29 does 
not affect cell viability. GFP and 
GFP_Sponge RAW264.7 cells were 
treated with RANKL (30 ng/ml) in the 
presence or absence of DOX (500 
ng/ml). Cell viability was measured over 
3 days by MTS assay (n=6). Growth 
curves in the presence or absence of 
DOX were superimposable. The lines 
without symbols illustrate linear growth 
curves with similar slopes. 
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osteoclast formation due to altered cell proliferation or viability, GFP or GFP_Sponge 
cells were cultured in the presence or absence of DOX for up to 3 days. Viable cells were 
quantified by MTS assay. All cultures displayed similar growth curves, suggesting that 
miR-29 did not promote osteoclast formation by regulating cell growth (Figure 3.6). 
 
Inhibition of miR-29 activity impairs RAW264.7 cell commitment to the osteoclast 
lineage. 
Some miRNAs regulate differentiation by promoting commitment to one cell fate 
at the expense of another. Since RAW264.7 cells have the potential to differentiate into 
osteoclasts or macrophages, we evaluated the effect of miR-29 knock-down on their 
lineage commitment. RAW264.7 cells have phagocytic properties, which are increased 
when committed to the macrophage fate. Therefore, we quantified phagocytosis in GFP 
and GFP_Sponge cells that had been induced toward osteoclastic differentiation by 
culture in the presence of RANKL for 24 hours. Phagocytosis was not altered in the GFP 
cells treated with DOX. However, when miR-29 activity was knocked-down in 
GFP_Sponge cultures treated with DOX, we observed increased phagocytic activity 
(Figure 3.7A, B). In addition, we analyzed the expression of genes associated with 
macrophage and osteoclast differentiation. DOX treatment of GFP_Sponge cells 
increased mRNA for macrophage markers F4/80 and Mac-1, and decreased mRNA for 
the early osteoclast marker NFATc1. In contrast, mRNA for the more mature osteoclast 
marker, Cathepsin K, was not affected (Figure 3.7C, D). These data suggest that miR-29 
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knock-down promotes the commitment of the RAW264.7 cell line to the macrophage 
lineage, at the expense of osteoclastogenesis. 
 
 
Figure 3.7. miR-29 knock-down supports RAW264.7 cell commitment to the 
macrophage lineage. GFP and GFP_Sponge RAW264.7 cells were induced toward 
osteoclastic differentiation by 24 hours RANKL treatment (30 ng/ml) in the presence or 
absence of DOX (500 ng/ml). A, Lineage commitment was assessed by phagocytosis 
assay. Cells were incubated for 1 hour with pHrodo bacterial particles (250 µg/ml). 
Cells that have phagocytosed the particles display red fluorescence (arrowheads). 
Nuclei were stained using DAPI reagent. Representative images of the cultures were 
captured using 10X magnification. Scale bar, 100 µm. B, Phagocytosis was quantified 
by measuring rhodamine fluorescence and normalized to DAPI fluorescence (n=6). C, 
Macrophage marker mRNAs, and D, osteoclast marker mRNAs were quantified by 
qRT-PCR and normalized to HPRT (n=3). * significantly different from no DOX, 
p<0.05. 
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Inhibition of miR-29 activity impairs RAW264.7 migration.  
In order to form osteoclasts, the migration of precursor cells is critical. We 
analyzed the ability of GFP and GFP_Sponge cells to migrate in response to a 
chemotactic stimulus using a modified Boyden Chamber (Transwell) assay. We found 
that GFP-expressing RAW264.7 cells displayed robust migration toward M-CSF 
supplemented culture medium (Figure 3.8). However, expression of the miR-29 sponge 
completely abrogated the capability of these osteoclast precursor cells to respond to the 
chemotactic agent, strongly indicating that miR-29 expression supports cell migration 
(Figure 3.8). 
 
Figure 3.8. miR-29 promotes the migration of RAW264.7 cells. A, GFP and 
GFP_Sponge cells were cultured for 24 hours with DOX (500 ng/ml). Cells were 
plated on transwells with 8-µm pores and allowed to migrate overnight toward M-CSF 
(30 ng/ml). The cells that migrated through the membrane were stained with crystal 
violet. B, Crystal violet staining was quantified. * significantly different from no M-
CSF, p<0.05, n=6. 
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Figure 3.9. Inhibition of miR-29 does not affect apoptosis of mature osteoclasts, or 
actin ring formation. A, GFP and GFP_Sponge RAW264.7 cells were differentiated for 
2 days with RANKL (30 ng/ml). The expression of the transgene was induced by 
addition of DOX (500 ng/ml) at day 3. Caspase-3 activity in mature osteoclast cultures 
was quantified after 4 days of differentiation (n=6). C, GFP and GFP_Sponge 
RAW264.7 cells were cultured on glass chamber slides for 4 days in the presence of 
DOX (500 ng/ml) and RANKL (30 ng/ml). Actin ring formation was evaluated by 
phalloidin staining (red), and nuclei were visualized with DAPI reagent (blue). 
Representative images were captured using 5X magnification. Boxed regions i and ii 
were visualized at 20X magnification. Actin rings are indicated by arrows. Scale bar, 100 
µm. 
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Figure 3.10. Luciferase analysis of miR-29 targets. Potential miR-29 targets were 
identified using a bioinformatic approach. Putative miR-29 binding sites (arrow heads) 
are present in the coding sequence and/or in the 3’UTR. The corresponding regions 
(between the vertical lines) were cloned into the pMIR-REPORT Luciferase vector, 
downstream of the Luciferase gene. The “±” symbol denotes the binding site deleted for 
the constructs shown in Figure 9. A, Putative miR-29 binding sites were identified in 
genes important for osteoclastogenesis. B, Luciferase activity was quantified in 
RAW264.7 cells co-transfected with a miR-29c inhibitor or a scrambled non-targeting 
control, and normalized to β-Galactosidase activity. Cells were treated with RANKL (30 
ng/ml) for 48 hours after transfection. C, Putative miR-29 binding sites were identified in 
genes important for cytoskeletal remodeling and cell migration. D, Luciferase activity. E, 
Potential miR-29 target genes associated with the macrophage lineage. F, Luciferase 
activity.* significantly different from scrambled, p<0.05, n=6. 
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Inhibition of miR-29 activity does not affect the apoptosis of mature osteoclasts or 
actin ring formation.  
Osteoclasts are terminally differentiated cells, and their ultimate fate is to undergo 
apoptosis (i.e. Figure 3.4B). It is possible that increased apoptosis could contribute to the 
decrease in number and size of osteoclastic cells observed in the presence of the miR-29 
sponge. Therefore, we analyzed Caspase-3 activity in GFP and GFP_Sponge cells 
cultured for 4 days in the presence of RANKL. The miR-29 sponge was only expressed 
during days 3 and 4 of culture, to allow initiation of osteoclastic differentiation. We did 
not detect a significant difference in Caspase-3 activity in cells expressing the miR-29 
sponge, compared with the other groups (Figure 3.9A). This suggests that miR-29 knock-
down does not affect the survival of mature osteoclasts. 
The formation of actin rings is a critical step for osteoclast-mediated bone 
resorption. To determine whether miR-29 knock-down affects actin ring formation, the 
GFP and GFP_Sponge were cultured for 4 days in the presence of RANKL and subjected 
to phalloidin staining. Although fewer and smaller multinucleated TRAP-positive cells 
were identified in miR-29 sponge cultures, their actin ring structures were intact (Figure 
3.9B panels i, ii). 
 
miR-29 targets RNAs important for the macrophage/osteoclast lineage.  
Our functional assays indicated that miR-29 is important for osteoclastogenesis, 
and promotes cell migration and osteoclast commitment. To better understand the 
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underlying mechanisms, we focused on identifying the mRNAs that are targeted by miR-
29 and whose functions are important in the macrophage/osteoclast lineage. We analyzed 
a list of genes expressed in osteoclastic cells (S-K Lee, unpublished data) for potential 
miR-29 targets, using several different algorithms for miRNA target prediction 
(miRanda, DIANA-mirExTra, PicTar, RNAhybrid). The list of potential targets was 
refined based on the ability of the miRNA to base pair with the target mRNA. We chose 
to clone and analyze 8 candidate genes with a well documented role in osteoclasts (Figure 
3.10A), or with a role in cell migration (Figure 3.10C), or with a role in the macrophage 
lineage (Figure 3.10E) (Tables 3.2, 3.4). 
We cloned the sequences containing the potential binding sites for miR-29 into a 
Luciferase reporter vector. Most constructs contained regions of interest ≥1 kb in length 
(Figure 3.10A, C, E). In these constructs, luciferase expression was driven by a strong, 
constitutive promoter, with the cloned regions serving as 3’ UTR for the Luciferase gene. 
Therefore, luciferase activity represents the regulatory activity of the sequence of interest. 
RAW264.7 cells were transiently transfected with the luciferase reporter plasmids and 
miR-29c inhibitor oligonucleotides. Increased luciferase activity in the presence of the 
miR-29 inhibitor would suggest that miR-29 targets that RNA region.  
 Of the RNAs with a well known function in osteoclastic cells, Calcitonin receptor 
(Calcr, Ctr), Trap, and Cathepsin K (Ctsk, Catk) had potential miR-29 binding sites. The 
potential miR-29 binding site in the Trap RNA was in the coding region, while those for 
Calcr and Ctsk were in the 3’ UTR. There were 2 potential miR-29 binding sites in the 
Calcr 3’ UTR. miR-29c inhibitor only increased luciferase activity from the construct 
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containing the Calcr 3’ UTR, suggesting that Calcr RNA is targeted by miR-29, whereas 
Trap and Ctsk are not (Figure 3.10B). The potential miR-29 binding site at base 2565 in 
the Calcr 3’ UTR had the most complementarity to miR-29 family members. When we 
deleted this miR-29 binding site, the ability of the miR-29 inhibitor to increase luciferase 
activity was lost, indicating that this sequence is specific for miR-29-mediated regulation 
(Figure 3.11A). 
For RNAs important for cytoskeletal organization, we analyzed Cell Division 
Control protein 42 (Cdc42) and SLIT-ROBO Rho GTPase activating protein 2 (Srgap2) 
(Figure 3.10C). Cdc42 is important for osteoclast function and migration and srGAP2 
participates in the same signaling pathway as Cdc42 (35). Although expressed in  
 
Figure 3.11. Deletion mutants of miR-29 binding sites. Putative miR-29 binding sites 
(marked with “±” in Figure 3.10) in the miR-29 target genes were deleted from pMIR-
REPORT Luciferase vectors. Luciferase activity was quantified in the RAW264.7 cells 
co-transfected with a miR-29c inhibitor or a scrambled non-targeting control, and 
normalized to β-Galactosidase activity. Cells were treated with RANKL (30 ng/ml) for 
48 hours after transfection. * significantly different from scrambled, # significantly 
different from 29c inhibitor in the wild type vector, p<0.05, n=6. 
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osteoclasts, srGAP2 has not been studied in the osteoclast lineage. There were potential 
miR-29 binding sites in the coding region and in the 3’ UTR of Cdc42, and the miR-29 
inhibitor increased luciferase activity 
from constructs containing either 
region, as well as the construct 
carrying the Srgap2 3’ UTR (Figure 
3.10D). Deletion of the potential 
miR-29 binding site in the coding 
region of Cdc42 abolished the ability 
of the miR-29c inhibitor to relieve 
repression of luciferase activity, 
indicating that this is a miR-29 
binding site (Figure 3.11B). 
Similarly, deletion of the potential 
miR-29 binding site in the Srgap2 3’ 
UTR construct abrogated the 
response of the construct to miR-29c 
inhibitor, indicating that the Srgap2 
3’ UTR is targeted by miR-29 
(Figure 3.11C). Deletion 
mutagenesis was not performed on 
the mouse Cdc42 3’ UTR construct 
 
Figure 3.12. Luciferase analysis of miR-29 
targets in the absence of RANKL. The 
luciferase constructs depicted in Figure 8 were 
co-transfected in RAW264.7 cells with a miR-
29c inhibitor or a scrambled control. Luciferase 
activity was quantified and normalized to β-
Galactosidase activity. * significantly different 
from scrambled, p<0.05, n=6. 
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because functional miR-29 binding sites in the human 3’ UTR were previously reported 
(101). 
With regard to genes associated with the macrophage lineage, we chose to 
examine G protein-coupled receptor 85 (Gpr85), Nuclear Factor I/A (Nfia), and Cd93 
(Figure 3.10E). NFIA expression inhibits both macrophage and osteoclast maturation, 
whereas GPR85 and CD93 are expressed during macrophage differentiation (53, 69, 102, 
103). Nfia and Cd93 had each 2 potential miR-29 binding sites in the 3’ UTR segment 
analyzed, while Gpr85 had one site. The miR-29c inhibitor increased luciferase activity 
for Gpr85, Cd93, and Nfia constructs, suggesting that these UTRs are miR-29 targets 
(Figure 3.10F). Deletion of the potential miR-29 binding site in the Gpr85 3’ UTR 
eliminated the miR-29c inhibitor-mediated increase in luciferase activity, indicating that 
this site is directly regulated by miR-29 (Figure 3.11D). For Cd93 (C1qRp), we deleted 
the potential miR-29 binding site at base 4403, and for Nfia, we deleted the miR-29 site at 
2125. These sites were chosen because, of the 2 present in the UTR construct, they had 
the most complementarity to miR-29 family members. The ability of the miR-29c 
inhibitor to relieve repression of luciferase activity in the Cd93 and Nfia mutant 
constructs was significantly decreased, but not totally abolished, likely due to the 
remaining functional miR-29 binding site in the construct (Figure 3.11E, F) (Table 3.4). 
It should be noted that the transfection studies shown in Figure 10 were 
performed in cells treated with RANKL, and similar trends were also noted in the 
absence of RANKL (Figure 3.12). Moreover, similar results were obtained when miR-
29a inhibitor was used instead of miR-29c inhibitor (data not shown). Overall, miR-29 
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may promote osteoclastogenesis by repressing RNAs important for differentiation to the 
alternative macrophage lineage. miR-29 targeting of RNAs important for osteoclast 
function and actin remodeling may allow subtle regulation of the rate of osteoclast 
differentiation (Table 3.6). 
 
DISCUSSION 
 
 Osteoclast commitment and maturation is an intricate, multi-step process, 
modulated by the combined activity of numerous signaling pathways. Since miRNAs can 
control the expression of several genes working in one or multiple pathways, it is likely 
that miRNAs orchestrate many of the changes in gene expression or activity necessary 
for osteoclast differentiation. In this study, we demonstrate that miR-29 plays a positive 
role in osteoclastogenesis. Its expression increases during differentiation, and miR-29 
knock-down impairs migration, commitment, and osteoclastogenesis. Our study is unique 
in that we validated a set of 6 novel miR-29 targets, which will contribute to our 
understanding of miR-29 function in osteoclasts and in other cell types (Table 3.6). 
The miR-29 family consists of four genes that encode 3 mature miRNAs. These 
genes are organized in genomic clusters: miR-29a and miR-29b-1 are transcribed as a 
single polycistronic primary transcript from mouse chromosome 6, and miR-29b-2 and 
miR-29c are also transcribed as a polycistronic transcript from chromosome 1 (104, 105). 
The three mature miRNAs of this family, miR-29a, -b, and -c, present high sequence 
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conservation and genomic organization in mouse, rat, and human, and nucleotides in 
positions 2-8, seed bases which are important for target recognition and binding, are 
identical (Table 3.5) (106). Although miR-29 family members may have overlapping 
targets, the mature miR-29 family members can be expressed at different levels, 
suggesting distinct transcriptional or post-transcriptional regulation of these genes (107, 
108). 
The expression of miR-29 family members increased during the osteoclast 
differentiation process, in both primary cultures and in RAW264.7 cells, and miR-29 
knock-down decreased osteoclast formation, suggesting that this miRNA family plays a 
positive role in differentiation. Studies from our laboratory and others demonstrate a 
positive role of miR-29 in the differentiation of other lineages, including osteoblastic and 
myogenic (87, 89, 109, 110). More recently, miR-29 was identified as one of 7 miRNAs 
that, in concert, can restrict proliferation and promote differentiation (111). Thus, the 
increase in miR-29 expression seen in the later stages of osteoclast differentiation may be 
in response to RANKL-induced differentiation program and withdrawal from the cell 
cycle. 
The Calcr 3’ UTR is targeted by miR-29, and CTR plays an important role in 
osteoclast function and cell survival. CTR is a G protein-coupled receptor that mediates 
the anti-apoptotic effect of calcitonin on mature osteoclasts, while inhibiting their 
resorption activity (112). Thus, the targeting of Calcr by miR-29 in mature osteoclasts 
could promote resorption. 
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We identified 3 new miR-29 targets that may be involved in commitment of 
precursor cells to the osteoclast lineage: Nfia, Cd93, and Gpr85 (Figures 3.10 and 3.11, 
Table 3.6). Transcript levels for these genes are decreased in primary cultures of 
osteoclast progenitors treated for 4 days with RANKL (S.K. Lee, unpublished data). 
NFIA is known to repress the differentiation of hematopoietic cells, including 
granulocytes and monocytes, and NFIA is a negative regulator of the M-CSF receptor in 
osteoclasts (68, 69). Since the M-CSF receptor is a positive regulator of 
osteoclastogenesis, the targeting of Nfia by miR-29, like miR-223, could contribute to 
differentiation (Figure 3.13A) (53). 
Table 3.6. Newly validated miR-29 targets and their biology. 
GENE BIOLOGY 
Calcr, Ctr 
Calcitonin receptor 
Calcitonin decreases resorption and increases OC 
survival (112). 
Cdc42 
Cell division cycle 42 
Promotes OC survival and differentiation. 
Regulates rate of actin ring formation (113). 
Srgap2 
SLIT-ROBO Rho GTPase 
activator protein 
Induces membrane protrusions. 
Knock-down reduces cell adhesion and increases 
migration (114, 115). 
Gpr85 
G protein-coupled receptor 
85 
Transiently induced by LPS in macrophages (103, 
116). 
Cd93 
complement component 1q 
receptor 1 
Promotes differentiation of monocytes into 
macrophages (102). 
Nfia 
nuclear factor I/A 
Negatively controls c-Fms. 
Over-expression inhibits osteoclast formation. 
Increased in Dicer-/- null osteoclast precursors (53, 69). 
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 In hematopoietic cells, the role of the other two miR-29 targets, CD93 and 
GPR85, is less well characterized. However, it is known that CD93 (C1qRp) is a 
transmembrane receptor regulating phagocytosis and cell adhesion, and is present on cells 
of the myeloid lineage (117). CD93 expression is increased with monocyte differentiation 
and macrophage activation (102, 118). Targeting of Cd93 by miR-29 could promote 
commitment to osteoclastogenesis, preventing monocytic differentiation. GPR85, also 
called SREB2 (superconserved receptor expressed in brain 2) is a G protein-coupled 
receptor abundant in neurons, and involved in determining brain size and functionality 
(116). In macrophages, GPR85 expression increases upon inflammatory stimulation with 
LPS (lipopolysaccharide) (103). Here, we showed that inhibition of miR-29 activity 
promotes the commitment of the RAW264.7 cells to the macrophage fate (Figure 3.7). It 
is possible that down-regulation of NFIA, CD93, and GPR85 by miR-29 could play a role 
in decreasing the potential of the cell to differentiate into the macrophage lineage, thus 
promoting osteoclastogenesis (Figure 3.13A). 
 
Figure 3.13. Model of miR-29 regulation of osteoclastogenesis. Schematic 
representation of the potential mechanisms regulated by miR-29 in the osteoclast 
lineage. A, Cell lineage commitment. B, Cell migration. 
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Osteoclast migration and fusion require extensive cytoskeletal reorganization, as 
does polarization and actin ring formation, initial steps for bone resorption. In this study, 
we demonstrated that knock-down of miR-29 family members, through the expression of 
an inducible miRNA sponge construct, suppressed the chemotactic migration of 
RAW264.7 cells (Figure 3.8). Decreased cell motility in the presence of the miR-29 
sponge likely contributed to the observed decrease in osteoclast size. However, not all 
functions involved in cytoskeletal remodeling, such as actin ring formation, were affected 
by knock-down of miR-29 activity (Figure 3.9B). It is possible that the factors or 
pathways specific for regulating actin ring formation may be less affected by miR-29 in 
osteoclasts.  
Cdc42 was identified as a miR-29 target in humans, and we confirmed miR-29 
targeting of the mouse homolog (Figures 3.10 and 3.11) (101). Cdc42 is a small GTPase 
that regulates actin remodeling, as well as cell cycle control and survival (119). Although 
not required for actin ring formation, Cdc42 regulates the rate of formation, as well as 
cell polarization (113). Cdc42 also regulates migration by controlling podosome turnover, 
and it is important for the movement of hematopoietic progenitors and macrophages 
toward chemotactic signals (120, 121). Although Cdc42 is critical for osteoclast 
formation and survival (113), Cdc42 transcript levels in osteoclasts are less than those 
found in macrophages or monocytes (122). Further, the levels of Cdc42 mRNA do not 
change dramatically during osteoclastic differentiation (123). It is possible that 
translational regulation by miR-29 family members could play a role in fine-tuning the 
Cdc42 levels during osteoclastogenesis. However, it is also important to consider that 
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Cdc42 transcripts are subject to alternative splicing, which can give rise to alternative 3’ 
UTRs. There is little known about Cdc42 splice variants in cells of the osteoclast lineage. 
It is possible that alternative 3’ UTR usage may be one means to vary the ability of 
Cdc42 to be targeted by miRNAs. 
srGAP2 is one of the novel miR-29 targets identified in this study. srGAP2 is a 
Rho-GTPase activating protein that participates in the same signaling pathway as Cdc42 
(114). Although srGAP2 function in osteoclasts has not been investigated, it has been 
shown to repress cell migration during neuronal development (114, 124) (Figure 3.13, 
Table 3.6). Knock-down of miR-29 activity could decrease cell motility, in part, by 
causing an increase in srGAP2. Intriguingly, in other cell systems, miR-29 was shown to 
target PTEN (tumor-suppressor phosphatase and tensin homolog), a lipid phosphatase 
involved in the phosphatidylinositol metabolism. Recent studies identified the 
suppression of PTEN as one mechanism by which miR-29 promotes migration in 
endothelial cells, breast cancer cells, and hepatocellular carcinoma cells (125). In 
RAW264.7 cells, activation of PTEN inhibits RANKL-mediated osteoclastogenesis and 
osteopontin-induced migration (126). It is possible that miR-29 knock-down could 
increase PTEN levels, and contribute to repressed migration of RAW264.7 cells (Figure 
3.13). 
It should be noted that our results appear to conflict with a recent report that 
lentiviral mediated over-expression of miR-29b in human CD14+ peripheral blood 
mononuclear cells reduced osteoclast formation (127). In that paper, Rossi et al. reported 
that miR-29b expression decreased during osteoclast formation, and that constitutive 
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over-expression of miR-29b decreased the expression of osteoclast marker genes and 
impaired collagen degradation. However, the miR-29 over-expression study by Rossi et 
al. differs from our work in several key areas. First, Rossi et al. used semi-sorted 
circulating human osteoclast precursors from the periphery, whereas we used murine 
bone marrow resident osteoclast precursors, which may not circulate. Second, the study 
by Rossi et al. did not report on the expression of other miR-29 family members, which 
should be present, since miR-29b is transcribed on the same pri-miRNA as miR-29c and 
miR-29a. Third, Rossi et al. over-expressed miR-29b. It has been shown that super 
physiological expression of a particular miRNA can alter global recruitment of miRNAs 
to the RISC (RNA-induced silencing complex), which can confound interpretation of a 
resulting cell phenotype (128, 129). Further, knock-down of components important for 
miRNA processing, such as DGCR8, Ago2, and Dicer1, inhibits osteoclastogenesis (53). 
It is possible that the miR-29b precursor over-expressed by Rossi et al. could compete for 
miRNA processing machinery, providing an alternative explanation for the inhibition of 
osteoclastogenesis observed by those investigators.  
In our study, we observed similar inhibitory effects on osteoclastogenesis when 
miR-29a, -29b or -29c were individually targeted by transiently transfected inhibitors 
(Table 3.5, Figure 3.3) and when their activity was inhibited by the miR-29 sponge 
competitive inhibitor (Figure 3.5C). These data, and the rest of the data herein, strongly 
support the conclusion that miR-29 family members promote osteoclastogenesis by 
several mechanisms. Whereas some miRNAs may act as “switches” for the commitment 
to one cell fate or another, many miRNAs are more subtle regulators of gene expression, 
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modulating the amplitude and tempo of a differentiation program (53, 58). miR-29 family 
members are likely subtle regulators of multiple osteoclast mRNA targets. 
 In conclusion, we demonstrated that miR-29 family members sustain migration 
and commitment of the precursor to osteoclastogenesis, and we validated 6 novel targets 
for this miRNA family. These data contribute to our understanding of the basic 
mechanisms regulating osteoclast differentiation, and provide insight into the function of 
miR-29 family members in cells of the hematopoietic lineage and in other tissue types. 
Dysregulation of miR-29 family members is implicated in the pathology of multiple 
malignancies, and in conditions such as diabetes and fibrosis, and aging (130). Additional 
studies, in vivo, will better define the role of miR-29 in osteoclastogenesis. It is possible 
that increased miR-29 levels could contribute to increased osteoclast formation with 
aging (131). 
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CHAPTER 4: 
 
Pathway analysis of microRNA expression profile during murine 
osteoclastogenesis 
 
CHAPTER ABSTRACT 
Osteoclasts are multinucleated cells specialized in degrading the mineralized bone 
matrix. Osteoclast differentiation and function are tightly regulated, to prevent excessive 
or insufficient bone resorption. Several control mechanisms participate in modulating 
osteoclastogenesis, and an increasing number of reports describe the role of microRNAs 
(miRNAs) in this process. Disrupting the expression of specific miRNAs can result in 
alterations of osteoclast formation and bone homeostasis. We and others have previously 
characterized 9 miRNAs whose levels change during osteoclast differentiation, and 
identified some of the target genes that mediate their function. However, little is known 
about changes in the miRNA expression profile during osteoclastogenesis. In this study, 
we isolated a murine primary bone marrow population enriched for osteoclast precursors, 
and used the Agilent microarray platform to analyze the expression of mature miRNAs 
after 1, 3, and 5 days of RANKL-driven differentiation. 93 miRNAs showed greater than 
2 fold-change during these early, middle, and late stages of osteoclastogenesis. Further, 
we compared the miRNA expression profile in cultures differentiated for 3 days with M-
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CSF and RANKL and undifferentiated cells cultured with M-CSF alone. 17 miRNAs 
showed more than 2 fold-change with RANKL treatment. Many of the miRNAs 
differentially regulated in the array were detected for the first time in osteoclasts, and we 
validated the expression of selected miRNAs by quantitative RT-PCR. We identified 
clusters of differentially expressed miRNAs during the course of osteoclastogenesis, and 
performed computational analyses to predict functional pathways that may be regulated 
by these miRNAs. Several miRNAs were predicted to regulate genes involved in 
cytoskeletal remodeling, a crucial mechanism for the migration of osteoclast precursors, 
their maturation, and bone resorbing activity. Our results suggest that clusters of miRNAs 
differentially expressed during the course of osteoclastogenesis converge on the 
regulation of several key functional pathways. Overall, this study identified miRNAs 
expressed during early, middle, and late osteoclastogenesis contributing to our 
understanding the molecular mechanisms regulating this complex differentiation process. 
 
INTRODUCTION 
 
The maintenance of bone homeostasis requires a tight control of the number and 
activity of osteoblasts, the bone-forming cells, and osteoclasts, the only cells able to 
resorb mineralized bone matrix. Osteoclast differentiation is an intricate process, 
regulated at multiple levels by transcription factors and post-translational modifications. 
In this process, myeloid progenitor cells differentiate into monocytes, commit to the 
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osteoclast lineage, migrate, and then fuse into multinucleated polykaryons, at the expense 
of the alternative macrophage fate. Several cytokines, including macrophage-colony 
stimulating factor (M-CSF, CSF1) and receptor activator of nuclear factor kappa-B ligand 
(RANKL), are responsible for driving osteoclastogenesis from multipotential 
hematopoietic progenitors. Several intracellular signaling pathways promote commitment 
to the osteoclast lineage, and converge on the activation of NFATc1, the master 
transcriptional regulator of osteoclastogenesis. NFATc1, in combination with other 
transcription factors, including PU.1, MITF, NFκB, and c-Fos, coordinates the expression 
of genes necessary for bone resorption, such as Cathepsin K, Tartrate-resistant acid 
phosphatase (Acp5, Trap), and Calcitonin receptor (2, 12, 83). 
More recently, a growing number of reports have demonstrated the important role 
of microRNAs (miRNAs) in osteoclast biology. miRNAs are short sequences of single-
stranded, non-coding RNA that act, for the most part, as post-transcriptional regulators of 
gene expression. This is achieved primarily by binding target mRNAs at sites frequently 
located in the 3’ untranslated region (UTR). However, miRNA binding sequences have 
been identified also in the coding region and in the 5’ UTR (84, 132). miRNA activity 
requires its incorporation in a RNA-induced silencing complex (RISC). Target 
recognition by the miRNA relies mainly on near-perfect base pair complementarity of the 
mRNA with the miRNA “seed region”, a 6-8 nucleotide-long sequence in the 5’ end of 
the miRNA. Upon target binding, repression of gene expression is accomplished by 
suppressing translation, and/or decreasing the stability of the mRNA. 
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The critical role of the miRNA processing pathway in the osteoclast lineage was 
described. In vitro, silencing of DiGeorge syndrome critical region 8 gene (DGCR8), 
Argonaute2 (Ago2), and Dicer1, key miRNA processing factors, decreased 
osteoclastogenesis and bone resorption (53). In vivo, deletion of Dicer in the myeloid 
lineage, using a CD11b promoter driven-Cre recombinase, and in mature osteoclasts, 
using a Cathepsin K promoter driven-Cre, led to the development of mild osteopetrosis, 
due to impaired osteoclast differentiation and activity (53, 54). These studies highlight 
the overall importance of miRNAs in regulating osteoclast biology, and allude to their 
potential as therapeutic targets for pathologies caused by excessive or insufficient 
osteoclast activity. However, little is known about the function of individual miRNAs in 
osteoclastogenesis.  
At the time of this writing, 9 miRNAs and only a few target genes have been 
analyzed in the osteoclast lineage (53, 55-58, 61-63, 65). Hundreds of miRNAs have 
been identified, and each miRNA can potentially regulate hundreds of mRNAs. Further, 
limited information is available about the miRNA expression profile during 
osteoclastogenesis, and how it changes during the course of differentiation. 
In the present study, we profiled miRNA expression during the early, middle, and 
late stages of osteoclastogenesis, in a population of primary murine bone marrow cells 
enriched for osteoclast progenitors. We also analyzed changes in miRNA expression in 
osteoclast precursors differentiated for 3 days with M-CSF and RANKL, when compared 
with undifferentiated cultures. Clusters of differentially expressed miRNAs were 
identified, and computational target prediction tools suggest that a set of miRNAs 
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expressed in the osteoclast lineage likely regulate pathways critical for cell motility, cell-
matrix interactions, axon guidance, and regulation of the actin cytoskeleton. 
 
MATERIALS AND METHODS 
 
Cell Culture. 
Primary osteoclast precursor cultures were established using bone marrow from 6-
8 week old C57BL/6 male mice, which had been enriched for osteoclast precursors by 
depletion of B220/CD45R-positive and CD3-positive cells (B and T lymphocytes, 
respectively). Briefly, bone marrow was isolated from femurs, tibias, and humeri, and 
depleted of erythrocytes by treatment with ammonium-chloride-potassium (ACK) buffer 
(Gibco Life Technologies, Grand Island, NY) (94). Cells were incubated with 
Phycoerythrin (PE)-conjugated primary antibodies for CD45R and CD3 (eBioscience, 
San Diego, CA), and with magnetically labeled anti-PE microbeads (MiltenyiBiotec, 
Auburn, CA). Magnetic-Activated Cell Sorting (MACS®) Column Technology 
(MiltenyiBiotec, Auburn, CA) was used to capture CD45R and CD3 positive cells in the 
column, and the flow-through contained a population of cells enriched for monocytic and 
non-lymphoid lineage cells. Flow cytometric analysis was performed to analyze the 
presence of CD45R and CD3 positive cells. Standard staining procedures were used to 
label the cells for flow cytometry. Non viable cells were identified by their ability to 
incorporate propidium iodide (PI). Flow cytometry was performed using a BD-FACS 
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Aria (BD Biosciences, San Jose, CA, USA), and data were analyzed using FlowJo 
software from Tree Star Inc (Ashland, OR, USA). Cells were cultured in α-MEM (Gibco 
Life Technologies, Grand Island, NY) supplemented with 10% FBS (Fetal Bovine 
Serum, Atlas Biologicals, Fort Collins, CO). Bone marrow-derived osteoclast precursor 
cells were cultured in the presence of 30 ng/ml recombinant Macrophage Colony-
Stimulating Factor (M-CSF) and 30 ng/ml murine recombinant RANKL (eBioscience, 
San Diego, CA) for up to 5 days. Bone marrow precursors were also cultured in the 
presence of 30 ng/ml M-CSF alone for 3 days. 
 
In Vitro Osteoclast Formation Assay. 
Cells were fixed in 2.5% glutaraldehyde in PBS, and TRAP activity was detected 
according to the manufacturer’s instructions using the Acid Phosphatase Leukocyte 
(TRAP) kit (Sigma-Aldrich). Osteoclast cultures were imaged using light microscopy. 
 
miRNA Microarray. 
 Primary osteoclast precursors were plated at 53,000 cells/cm2. Total RNA was 
isolated from differentiating cultures using the miRNeasy Mini kit (Qiagen, Valencia, 
CA). On-column DNase treatment was performed to reduce contamination with genomic 
DNA, and an additional treatment with RQ1 DNase (Promega, Madison, WI) was 
performed prior to gene expression analysis. RNA concentration and purity were assessed 
by spectrophotometric analysis. The quality of small RNAs in each sample was 
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determined using the 2100 Bioanalyzer assay (Agilent Technologies, Santa Clara, CA). 
200 ng of total RNA were labeled using miRNA Microarray System with miRNA 
Complete Labeling and Hyb Kit (Agilent Technologies). According to the manufacturer’s 
instructions, the samples were hybridized for 20 hours onto a mouse miRNA Microarray, 
Release 15.0, 8x15K (based on Sanger miRBase release 15.0), containing 627 mouse 
mature miRNA probes (Agilent Technologies). Hybridized and washed array slides were 
scanned at 5 µm resolution using an Agilent SureScan Microarray Scanner (Agilent 
Technologies). Image processing was completed using Feature Extraction Software 
(Agilent Technologies). We acknowledge Dr. David Willmot for technical assistance 
with the microarray analysis. 
 
Microarray Data Analysis. 
 Microarray data were normalized and analyzed using the GeneSpring GX 
software (Technology 29152_v.17_0, Agilent Technologies). 4 biological replicates were 
used for each sample set. miRNAs detected in at least one sample were subjected to 
quantile normalization to allow comparison between the microarray chips, and relative 
expression is presented as log(base 2). One-way Analysis of Variance (ANOVA) was 
performed on miRNAs expressed during the time course of osteoclast differentiation 
analyzed (days 1, 3, and 5). Student’t t test was performed on miRNAs expressed in 
undifferentiated (cultured in the presence of M-CSF alone) and differentiated (cultured in 
the presence of M-CSF and RANKL). For both data sets, miRNAs showing >2 or <-2 
fold-change, with p<0.01, were considered statistically significant. A hierarchical 
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clustering analysis was used to organize the genes based on similarities in their 
expression profiles. A list of putative miRNA targets was identified using the prediction 
algorithm DNA Intelligent Analysis (DIANA) DIANA-microT-CDS (v5.0). The 
predicted miRNA targets were annotated into functional pathways using DIANA-
miRPath (v2.0) (http://diana.imis.athena-
innovation.gr/DianaTools/index.php?r=site/index). The complete data set has been 
submitted to NCBI-GEO (National Center for Biotechnology Information – Gene 
Expression Omnibus), and is available at the accession number GSE53017. 
  
Quantitative Real time PCR. 
 miRNA expression levels were analyzed using the TaqMan MicroRNA Assay 
(Life Technologies, Grand Island, NY). According to the manufacturer’s instructions, 
22.5 ng of RNA were reverse transcribed with specific primers to generate cDNA. The 
expression of miR-365, miR-99b, and miR-451 was detected by qPCR in a MiQ qPCR 
cycler (Bio-Rad) and normalized to U6 small nuclear RNA (RNUB6) levels, using the 
absolute quantification method. Data are presented as mean ± SEM. Data were analyzed 
by one-way ANOVA with Bonferroni post-hoc test as appropriate (KaleidaGraph, 
Synergy Software, Reading, PA). 
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RESULTS AND DISCUSSION 
 
Differential miRNA expression during in vitro osteoclastogenesis.  
 Mouse bone marrow is a widely used source of primary osteoclast progenitors 
for in vitro analyses. However, bone marrow represents a highly heterogeneous 
population, containing not only monocytes, but also megakaryocyte precursors, 
terminally differentiated macrophages and neutrophils, and, in higher percentage, 
lymphocytes. Our unpublished results indicate that 25-30% of total bone marrow is 
B220+ and 5-7% is CD3+ after erythrocyte depletion (Dr. S.K. Lee, personal 
communication, unpublished data). In addition, the majority of the efficient osteoclast 
precursors is contained within the B220-/CD3-/CD11b-/lo population in the bone marrow 
(43, 133). Therefore, we sought to decrease the heterogeneity of this precursor 
population, prior to the initiation of osteoclastogenesis, by depleting the lymphocytic 
cells. Mouse bone marrow cells were subjected to MACS sorting using CD45R and CD3 
antibodies. Flow cytometric analysis confirmed that this procedure depleted 93-95% of T 
and B cells, thereby decreasing the heterogeneity of the marrow cells that were 
subsequently plated for experiments (Figure 4.1A). We cultured mouse bone marrow-
derived osteoclast precursors in the presence of M-CSF and RANKL for up to 5 days. At 
days 1, 3, and 5 of culture, osteoclast formation was monitored by TRAP staining, and 
total RNA was harvested (Figure 4.1B). Under these conditions, osteoclast number 
increased progressively, and mRNA levels for the osteoclast markers TRAP and 
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Cathepsin K were increased from day 1 to day 3, and maintained at day 5, as we 
previously reported (62) (Figure 3.2E,F). 
 The Agilent mouse miRNA microarray that we used contained 627 probes for 
mature miRNAs. In our sample set, 258 miRNAs were significantly detected at least at 
one time point. 142 of these miRNAs were significantly changed during the time course 
investigated, and several were identified for the first time in the osteoclast lineage. 
Among the significantly changed miRNAs, 93 miRNAs showed > ± 2 fold-change. 49 
miRNAs were up-regulated over time, whereas 44 were down-regulated (Figure 4.2). 
 In regards to miRNA expression after 3 days in culture, 43 miRNAs were 
significantly changed with M-CSF and RANKL treatment in comparison with M-CSF 
 
Figure 4.1. MACS sorting depleted lymphocytes from bone marrow-derived 
osteoclast cultures. (A) Bone marrow cells were depleted of CD45R+ and CD3+ cells by 
MACS sorting, using CD45R and CD3 antibodies. The negative population, constituted 
by non-lymphoid cells and enriched for monocytes, was collected and analyzed by flow 
cytometry. The gated population identifies the CD45R/CD3+ cells (purple) (n=3). (B) 
The enriched population of bone marrow-derived osteoclast precursors was 
differentiated in the presence of 30 ng/ml, each, M-CSF and RANKL for up to 5 days. 
Representative images of TRAP stained cultures after 1, 3, and 5 days of differentiation 
were captured using 10X magnification. Scale bar, 100 µm (n=3). 
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Figure 4.2. miRNA expression profiles during osteoclastogenesis. (A) Heat map of 
the 93 miRNAs showing > ± 2 fold-change over 5 days of osteoclast differentiation. 
Fold-change was calculated between day 1 and day 3, day 1 and day 5, and day 3 and 
day 5. Hierarchical cluster analysis on gene expression divided the miRNAs in 7 groups. 
Blue represents low expression, red high expression, and yellow intermediate 
expression. (B) Schematic overview of the microarray results. 
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treatment alone, and 17 miRNAs showed > ± 2 fold-change. 9 miRNAs were up-
regulated in the presence of RANKL, whereas 8 were decreased (Figure 4.3). 
 
Verification of the microarray results.  
 To verify the results of the microarray experiment, we used quantitative RT-PCR 
(qRT-PCR) to confirm changes in the levels of 3 miRNAs, the expression of which had 
not been previously reported in the osteoclast lineage: miR-365, miR-99b, and miR-451 
(Figure 4.4, Table 4.1). We observed that miR-365-3p and miR-99b-5p were 2 miRNAs 
strongly up-regulated in day 5 cultures (Figures 4.8A, 4.9A). qRT-PCR confirmed that 
their levels increased 12 fold in the differentiating cultures (Figure 4.4A). Further, the 
expression of miR-365 and miR-99b was significantly induced by 3 days of M-CSF and 
RANKL treatment, when compared with cells cultured in the presence of M-CSF alone 
(Figure 4.4C,D). This suggests that the up-regulation of miR-365 and miR-99b levels 
during the course of osteoclastogenesis is likely associated with the progression of the 
differentiation program, rather than time in culture. 
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 The function of miR-365 in 
osteoclastogenesis or in 
hematopoietic cells has not been 
investigated. However, we found 
this miRNA was of interest because, 
although mature miR-365 is 
transcribed from two independent 
genetic loci (on mouse chromosomes 
11 and 16), the expression of miR-
365 from the chromosome 16 locus 
is activated by Sp1 and NFκB, two 
transcription factors that promote 
osteoclastogenesis (29, 134). miR-
99b was of interest because it is up-
regulated in dendritic cells and 
monocytes during inflammation 
(135, 136). Further, TNFα (tumor 
necrosis factor α) signaling is a key 
pathway in promoting 
osteoclastogenesis, and Tnfα, Tnfrsf4 
(Tumor Necrosis Factor Receptor 
Superfamily, Member 4), and Traf2  
 
Figure 4.3. miRNA expression profile after 3 
days of culture with M-CSF and RANKL. Heat 
map of the 17 miRNAs showing > ± 2 fold-
change in the presence or absence of RANKL. 
Hierarchical cluster analysis grouped the 
miRNAs based on their expression levels. Blue 
represents low expression, red high expression, 
and yellow intermediate expression. 
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Figure 4.4. Validation of miRNA microarray results. (A,B) The expression of 
selected miRNAs that changed > ± 2 folds during the course of osteoclastogenesis was 
analyzed by qPCR. (A) miR-365 and miR-99b expression; (B) miR-451 expression. (C-
E) Selected miRNAs that showed greater than ± 2 fold-change in cells treated with M-
CSF and RANKL (M+R) versus cells treated with M-CSF (M) alone for 3 days were 
quantified. (C) miR-365 expression; (D) miR-99b; (E) miR-34b. Gene expression was 
normalized to U6. n=4; * significantly different from day 1 (p<0.01). 
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(TNF receptor-associated factor 2), were recently identified as miR-99b targets in other 
cell types (136-139). Interestingly, miR-99b is transcribed in an evolutionary conserved 
cluster that includes let-7e and miR-125a, all of which were significantly up-regulated 
during osteoclastogenesis, as assessed by our microarray (Figure 4.7A) (140). 
 In contrast, miR-451 expression was dramatically decreased over 5 days of 
osteoclast differentiation (Figure 4.4B). Several reports have revealed that miR-451 
expression is required for erythroid differentiation and homeostasis (141, 142). 
Therefore, it is possible that the high levels of miR-451 detected at day 1 are due to the 
presence of erythrocyte precursors in the cultures, which will not survive the 
differentiation with M-CSF and RANKL. Indeed, we could not detect expression of miR-
451 by qRT-PCR in the bipotential mouse monocytic cell line RAW264.7 (data not 
shown).  
 In regard to miRNAs significantly changed at day 3 of differentiation with M-
CSF and RANKL, in comparison with undifferentiated cultures, we confirmed that miR-
34b-5p is significantly increased in the presence of RANKL (Figure 4.3, Figure 4.4E). 
miR-34b belongs to the miR-34 family of miRNAs, which were previously identified as 
principal players in the p53-mediated regulation of apoptosis (143). The role of miR-34b 
in the osteoclast lineage is unknown. However, the function of miR-34b in the regulation 
of hematopoiesis has been investigated. The genomic region encoding for the miR-34b 
gene is frequently deleted in chronic lymphocytic leukemia, and miR-34b targets the anti-
apoptotic gene Tcl-1 (T-cell leukemia/lymphoma 1) (144). In addition, miR-34b inhibits 
the expression of CREB (cAMP response element-binding protein), a key transcriptional  
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Table 4.1. Changes in miRNA profile during the progression of murine 
osteoclastogenesis, confirmed by other microarray studies. Published studies in 
RAW264.7 cell line and mouse bone marrow macrophages (BMMs) confirm the 
expression pattern for 17 of the 97 miRNAs regulated during the course of 
osteoclastogenesis (61, 67). 
miRNA 
Expression during 
osteoclastogenesis 
Experimental system References 
let-7a-5p ↑ BMMs, RAW264.7 (61, 67) 
let-7e-5p ↑ BMMs, RAW264.7 (61, 67) 
let-7f-5p ↑ BMMs, RAW264.7 (61, 67) 
miR-100-5p ↑ RAW264.7 (67) 
miR-125a-5p ↑ RAW264.7 (67) 
miR-125b-5p ↑ RAW264.7 (67) 
miR-146a-5p ↑ RAW264.7 (67) 
miR-146b-5p ↓ RAW264.7 (67) 
miR-185-5p ↑ RAW264.7 (67) 
miR-29b-3p ↑ 
RAW264.7, bone marrow-derived 
osteoclast precursors 
(62, 67) 
miR-338-3p ↓ RAW264.7 (67) 
miR-365-3p ↑ RAW264.7 (67) 
miR-378-3p ↑ RAW264.7 (67) 
miR-674-3p ↑ RAW264.7 (67) 
miR-689 ↓ RAW264.7 (67) 
miR-98-5p ↑ BMMs, RAW264.7 (61, 67) 
miR-99a-5p ↑ RAW264.7 (67) 
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regulator of hematopoiesis (145). These observations indicate that proper expression of 
miR-34b is necessary for the progression of hematopoietic differentiation. Therefore, 
changes in the expression of miR-34b may be involved in the control of 
osteoclastogenesis. 
 We compared our microarray results with other published murine miRNA profile 
analyses in osteoclastic cultures. The expression pattern that we observed for 17 of the 
significantly regulated miRNAs was similar to what observed in a 24 or 82 hour 
RANKL-driven RAW264.7 cell differentiation, and in a 24-hour RANKL-treatment of 
bone marrow macrophages (Table 4.1) (61, 67). However, a few discrepancies were 
noted in miRNA expression trends between our microarray data and those published by 
other investigators. These are likely attributable to differences in the experimental 
designs, most notably differences in the percentage of osteoclast precursor cells used and 
the time in culture. Our study is unique in that we analyzed an enriched population of 
primary osteoclast precursors from the bone marrow, and evaluated miRNA expression 
during early, middle, and late phases of differentiation. 
  
Target prediction and correlated pathways for miRNA expression clusters.  
 The 93 miRNAs that showed greater than ± 2 fold-change with osteoclast 
differentiation were analyzed by hierarchical clustering. Based on their level of 
expression and change during differentiation, the miRNAs were divided into 7 clusters 
(Table 4.2, Figures 4.5-4.11, Figure 4.2). In an attempt to understand how these changes  
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in miRNA expression might 
influence osteoclastogenesis, 
we performed a computational 
target prediction analysis. 
Potential target RNAs for up- 
or down-regulated miRNAs 
from each cluster were 
identified using the prediction 
algorithm DIANA-microT-
CDS (v5.0). This algorithm 
recognizes potential miRNA 
binding sites located in the coding sequence and in the 3’ UTR of an mRNA, based on 
complementary pairing with nucleotides in position 1-9 at the 5’ end of the miRNA (i.e. 
the seed binding region). Additional features taken into consideration include 
conservation of the sequence element across species and accessibility of the target site 
(146, 147). The potential miRNA targets for each miRNA cluster were then subjected to 
KEGG (Kyoto Encyclopedia of Genes and Genomes) pathway analysis, using the 
DIANA-miRPath (v2.0) software. This algorithm calculates the significance for all the 
miRNA-mRNA pairs in a pathway, and then combines them into a merged P-value for 
each pathway (148). The results are reported as heat maps, and the pathways are clustered 
based on significance levels. The more intense red color indicates higher probability that 
a specific pathway is significantly enriched with target genes for a certain miRNA. 
Table 4.2. miRNA clusters. Hierarchical clustering of 
the miRNAs significantly changed during osteoclast 
differentiation generated 7 subgroups. 
Cluster number Name/Description 
1 Highly expressed 
2 Modestly expressed down-regulated 
3 Modestly expressed up-regulated 
4 Well expressed up-regulated 
5 Well expressed down-regulated 
6 Most down-regulated over time 
7 Most up-regulated over time 
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Figure 4.5. Cluster 1, highly expressed miRNAs during osteoclastogenesis. (A) 
miRNA heat map. The dendrogram shows the similarities between the expression 
profiles of the significantly changed miRNAs. Down-regulated miRNAs are indicated 
by the “*” symbol. Blue represents low expression, red high expression, and yellow 
intermediate expression. (B) Up-regulated miRNAs and predicted pathways heat map. 
Red color indicates lower p values (more significant), and higher interaction of each 
miRNA with a specific molecular pathway. (C) Down-regulated miRNAs and predicted 
pathway heat map. Significant miRNA-pathway interaction p<0.001. 
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 Cluster 1 is composed of highly expressed miRNAs, and contains miRNAs that 
are both up- and down- regulated during osteoclastogenesis. Therefore, separate pathway  
analysis was performed for the up- and down- regulated miRNAs. Among the highly 
expressed and up-regulated miRNAs is miR-29b, a member of the miR-29 family (Figure 
4.5A). We and others previously showed that the expression of all miR-29 family 
members increases during osteoclastogenesis (62, 67) (Figure 3.2A). In addition, we 
demonstrated that miR-29 promotes osteoclast commitment and migration, and is critical 
for osteoclast formation. We validated several novel miR-29 targets in the osteoclast 
lineage, including calcitonin receptor. Further, miR-29 targets genes important for the 
macrophage lineage, Nfia (Nuclear factor 1/A), Cd93, and Gpr85 (G protein coupled 
receptor 85); and genes modulating cell migration, including Cdc42 (Cell division control 
protein 42) and Srgap2 (SLIT-ROBO Rho GTPase activating protein 2) (62). With regard 
to miR-29b, the pathway analysis suggests that functions such as cell-matrix interactions, 
focal adhesion, and PI3K/Akt, to be most significantly associated with miR-29 (Figure 
4.5B). Several predicted miR-29 targets within these pathways have been experimentally 
confirmed. These include mRNAs for a large number of extracellular matrix proteins 
(collagens, laminins), the tumor suppressor Pten, Igf1 (insulin growth factor 1), and Mcl1 
(myeloid cell leukemia 1) (149-152). Overall, these observations suggest that the 
pathway prediction analysis for the individual miRNAs is, at least in part, validated by 
experimental data. 
 The validity of this pathway clustering approach is further supported by analysis 
of the miRNA family formed of miR-99a, miR-99b, and miR-100. Each these miRNAs is  
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up-regulated during the course of osteoclastogenesis, although with different amplitude. 
miR-99a-5p belongs to expression cluster 4, miR-99b-5p to cluster 7, and miR-100-5p to  
cluster 3 (Figures 4.7A, 4.8A, and 4.11A). KEGG pathway analysis predicted, with a 
high degree of confidence (p<0.001), miR-99b regulation of the mTOR (mammalian 
target of rapamycin) pathway, whereas association of miR-99a and miR-100 with the 
mTOR pathway was predicted with lower confidence (p<0.005) (Figures 4.7B, 4.8B, and 
4.11B). Remarkably, several studies demonstrated the role of the miR-99 family in 
repressing mTOR signaling in different cell systems, including wound healing 
keratinocytes, as well as prostate, endometrial, and pancreatic cancer cells (153-156). In 
our study, numerous clusters of miRNAs, both up- and down-regulated during the course 
of osteoclast differentiation, were predicted to target components of the mTOR pathway. 
 
Figure 4.6. Cluster 2, 
modestly expressed 
miRNAs down-
regulated during 
osteoclastogenesis. 
(A) miRNA heat map. 
Blue represents low 
expression, red high 
expression, and yellow 
intermediate expression. 
(B) Predicted pathways 
heat map. Red color 
indicates lower p 
values. 
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Cluster 4 appears to be particularly enriched in miRNAs with potential targets in the 
mTOR pathway (Figure 4.8B). Clusters of differentially regulated miRNAs are predicted 
to target both positive and negative regulators of the mTOR pathway, as represented in 
the diagram in Figure 4.12.  
 
Figure 4.7. Cluster 3, modestly expressed miRNAs up-regulated during 
osteoclastogenesis. (A) miRNA heat map. Blue represents low expression, red high 
expression, and yellow intermediate expression. (B) Predicted pathways heat map. Red 
color indicates lower p values. 
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Figure 4.8. Cluster 4, well expressed miRNAs up-regulated during 
osteoclastogenesis. (A) miRNA heat map. Blue represents low expression, red high 
expression, and yellow intermediate expression. (B) Predicted pathways heat map. Red 
color indicated lower p values. 
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Figure 4.9. Cluster 5, well expressed miRNAs down-regulated during 
osteoclastogenesis. (A) miRNA heat map. Blue represents low expression, red high 
expression, and yellow intermediate expression. (B) Predicted pathways heat map. Red 
color indicates lower p values. 
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Figure 4.10. Cluster 6, miRNAs most down-regulated during osteoclastogenesis. 
(A) miRNA heat map. Blue represents low expression, red high expression, and yellow 
intermediate expression. (B) Predicted pathways heat map. Red color indicates lower p 
values. 
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 In osteoclasts, mTOR has been implicated in the regulation of apoptosis. Crucial 
signaling pathways triggered by M-CSF, RANKL, and TNFα converge on the activation 
of S6K (p70 ribosomal protein S6 kinase), a main effector of the mTOR signaling 
cascade. By regulating the process of translation, mTOR promotes osteoclast 
differentiation, survival, and bone-resorbing activity (157, 158). Although miRNA-
mediated modulation of mTOR factors has been widely investigated in other biological 
systems, this represents a novel area of research in the bone field. 
 
Figure 4.11. Cluster 7, miRNAs most up-regulated during osteoclastogenesis. (A) 
miRNA heat map. Blue represents low expression, red high expression, and yellow 
intermediate expression. (B) Predicted pathways heat map. Red color indicates lower p 
values. 
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 KEGG pathway analysis showed that several miRNAs from clusters 1, 3, and 4 
were predicted to target extracellular matrix-receptor interactions, regulators of the actin 
cytoskeleton, focal adhesion, and axon guidance (Figures 4.5B,C, 4.7B, 4.8B). As a 
representative example, the predicted target genes in the axon guidance pathway are 
depicted in Figure 4.13. Pathway prediction analysis indicated that both genes with a 
positive and negative role in axon guidance were predicted to be regulated by 
differentially expressed miRNAs. This suggests that further analyses are necessary to  
 
Figure 4.12. Positive and negative regulators of the KEGG mTOR signaling 
pathway are potential targets of up- and/or down-regulated miRNA clusters. 
103 
 
validate the individual miRNA-target interactions and the function of clusters of miRNAs 
in regulating this pathway. 
 Likewise, pathway analysis for miRNAs up- and down-regulated after 3 days of 
osteoclastogenic differentiation with M-CSF and RANKL indicated that focal adhesion 
and axon guidance were predicted targets for various miRNAs (Figure 4.14). Osteoclasts 
do not use focal adhesions to adhere to the bone surface. However, several proteins that 
belong to the KEGG functional pathway for focal adhesion participate in the formation of  
 
Figure 4.13. Positive and negative regulators of the KEGG axon guidance pathway 
are potential targets of up- and/or down-regulated miRNA clusters. 
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podosomes and actin rings, which are critical for osteoclast adhesion. These include 
integrins and proteins of the Rho GTPase signaling pathway. Similarly, although axon 
guidance is usually studied in regard to neuronal development, numerous factors within  
this KEGG pathway play an essential role in the osteoclast lineage, such as ephrins, 
semaphorins, and Rho GTPases (76, 159, 160). Moreover, many signaling cascades that 
regulate focal adhesion and axon guidance, as well as extracellular matrix-receptor 
interaction, converge on reorganization of the actin cytoskeleton. This is a key process 
that regulates a variety of biological functions, including cell motility, morphology, and 
attachment, as well as gene expression, differentiation, and apoptosis. Cytoskeletal 
 
Figure 4.14. Pathway prediction analysis for miRNAs differentially expressed 
after 3 days of M-CSF and RANKL treatment versus M-CSF alone. (A) Up-
regulated miRNAs and predicted pathways heat map. (B) Down-regulated miRNAs 
and predicted pathways heat map. Red color indicates lower p values. 
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remodeling and cell migration are fundamental for osteoclast formation and bone 
resorption activity, and they are tightly controlled at multiple levels (161). We and others 
have previously shown that miRNAs can modulate osteoclast motility and activity (55, 
62, 63). However, a complete understanding of the miRNAs involved in fine tuning the 
regulation of cytoskeletal reorganization is lacking. Our study contributes to the 
identification of miRNAs that may play a role in this function. 
 We performed pathway analysis on miRNAs down-regulated upon 3 days of 
RANKL treatment. This revealed that the KEGG pathway for osteoclast differentiation 
was predicted to be regulated by a subset of miRNAs, miR-340-5p, miR-362-3p, miR-
500-3p, which had previously not been investigated in osteoclasts or in hematopoiesis 
(Figure 4.14B). Predicted targets for these miRNAs include proteins involved in signal 
transduction for the PI3K/Akt signaling and the MAPK signaling, transcription factors 
such as Nfatc1, c-Fos, and Nfκb, and osteoclast markers like calcitonin receptor and 
integrin β3. Although, further experimental validation is needed, these data suggest that 
this subset of miRNAs may be critical in the regulation of osteoclastogenesis. 
 
CONCLUSIONS 
 
 Osteoclastogenesis is an intricate multi-step process, initiating with the 
proliferation and commitment of mononucleated precursors, and culminating in the 
formation of large bone-resorbing polykaryons. In this study, we identified a profile of 
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miRNAs differentially expressed in the various stages of osteoclastogenesis in primary 
cultures. Pathway analysis showed that a large number of miRNAs detected in the 
microarray were predicted to target genes involved in the interaction between cells and 
extracellular matrix, axon guidance, focal adhesion, and remodeling of the actin 
cytoskeleton. An increasing number of studies have revealed the relevance of miRNAs in 
osteoclast biology, making them appealing targets for the development of therapeutic 
strategies for bone disease. However, our knowledge of the function of specific miRNAs 
in this lineage is still limited. This study provides important information on miRNAs with 
the potential to regulate osteoclast differentiation; such information will contribute to the 
development of therapies for skeletal pathologies caused by alterations in bone resorption 
activity. 
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CHAPTER 5: 
 
SUMMARY, SIGNIFICANCE, AND CONCLUSIONS 
 
Summary 
 
The purpose of the studies described in this dissertation was to improve our 
knowledge of the molecular mechanisms by which miRNAs regulate genes important for 
osteoclast differentiation and function. 
First, we determined that the miR-29 family members, miR-29a, -29b, and -29c, 
increase during murine osteoclastogenesis. We also showed that inhibition of miR-29 
family members impairs osteoclast formation in vitro. In addition, we developed a stably 
transduced RAW264.7 cell line expressing a doxycycline-inducible miR-29 competitive 
inhibitor (sponge construct). Using this cell line as a tool, we showed that miR-29 knock-
down inhibits commitment and migration of osteoclasts precursors. However, miR-29 
knock-down does not affect cell viability, actin ring formation, or apoptosis in mature 
osteoclasts. We also identified six novel miR-29 targets, which play a role in mediating 
its function in the osteoclast lineage. These include RNAs critical for cytoskeletal 
organization, such as Cell Division Control protein 42 (Cdc42) and SLIT-ROBO Rho 
GTPase activating protein 2 (Srgap2). Moreover, miR-29 targets RNAs associated with 
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the macrophage lineage: G protein-coupled receptor 85 (Gpr85), Nuclear Factor I/A 
(Nfia), and Cd93. In addition, Calcitonin receptor (Calcr), which regulates osteoclast 
survival and resorption, is a novel miR-29 target. Thus, we identified miR-29 as a 
positive regulator of osteoclast formation, which inhibits RNAs important for 
cytoskeletal organization, commitment, and osteoclast function (Chapter 3) (62). 
 Second, we isolated a murine primary bone marrow population enriched for 
osteoclast precursors, and analyzed the expression of mature miRNAs during the early, 
middle, and late stages of osteoclastogenesis. Further, we compared the miRNA 
expression profile in day 3 undifferentiated and differentiated cultures of osteoclast 
precursors. We identified clusters of differentially expressed miRNAs during the course 
of osteoclastogenesis, and performed computational analyses to predict functional 
pathways that may be regulated by these miRNAs. Several miRNAs were predicted to 
regulate genes involved in cytoskeletal remodeling, a crucial process for the migration of 
osteoclast precursors, their maturation, and bone resorbing activity. Therefore, miRNA 
profiling of differentiating osteoclast precursors highlighted novel miRNAs that may 
regulate osteoclast differentiation and function (Chapter 4). 
The main challenge in understanding the functional significance of alterations in 
the miRNA expression profile is the identification of target mRNAs. A single miRNA 
can regulate the expression of several hundred genes, and validation of true miRNA-
mRNA target interactions requires experimental approaches similar to the ones used in 
Chapter 3. To determine potential miRNA-mRNA interactions for analysis, 
computational target prediction is usually the first step, since it helps develop the 
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hypotheses. This approach is biased by the design of the algorithm used, and frequently 
by the investigator’s interest in specific genes or biological mechanisms. Alternatively, 
pull-down assays for the proteins involved in miRNA biogenesis, such as Argonaute2, 
can be used to identify physical interactions between miRNAs and mRNA sequences 
(162). Both of these methods present advantages and limitations.  
For example, computational analysis evaluates hundreds of genes at the same 
time; although the results of such analyses include a large number of false positive and 
false negative interactions. Thus, it is necessary to directly validate the predicted miRNA-
mRNA interactions (162, 163). Pull-down assays, on the other hand, can lead to the 
identification of direct miRNA binding sequences in target mRNAs in the cell. However, 
this type of analysis is technically challenging, demands a high level of expertise, and 
additional tests are required to confirm that the identified miRNA-mRNA interactions 
actually regulate the protein product (163).  
A more comprehensive approach would combine proteomic analyses with 
computational target prediction and miRNA expression data, generated by microarray or 
deep-sequencing. This approach could reveal an inverse relationship between the 
expression of a certain miRNA and potential mRNA and protein targets in the data set. 
For example, a recent study by Ou et al. integrated miRNA deep-sequencing results on 
PBMCs from osteopetrotic patients with quantitative proteomics and bioinformatics for 
target prediction. Here, a reciprocally expressed miRNA-target pair was identified. miR-
320a was decreased in osteopetrosis, whereas the Ras-like GTPase ARF1 (ADP 
ribosylation factor 1) was up-regulated. Arf1 was identified as a novel miR-320a target, 
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and it belongs to a family of GTPases important in the regulation of osteoclast 
polarization and formation of the sealing zone (64, 164). Such studies in osteoclasts could 
help identify new miRNAs and target genes important in the development of pathological 
conditions, and potential candidates for therapy. 
 
Significance 
 
 We and others demonstrated that miRNAs are essential regulators of cell 
differentiation and activity. In addition, alterations in miRNA expression are often 
detected in pathological conditions, including degenerative diseases, cancer, and auto-
immune conditions (8). Due to their ability to regulate cell physiology and their 
documented dysregulation in disease, miRNAs appear as attractive candidates for the 
development of diagnostic and prognostic tools, as well as for the development of 
miRNA-based therapeutics. With regard to miRNA-based therapeutics, the potentially 
pathological effect of a miRNA over-expressed during disease could be blocked by 
specific inhibitors, whereas the levels of a miRNA down-regulated during pathogenesis 
could be restored using mimics. In this way, it may be possible to modify the miRNA 
levels and, as a consequence, change the phenotype of a particular cell or tissue. 
 We showed that the miR-29 family of miRNAs promotes osteoclast 
differentiation (62). Therefore, understanding the mechanisms by which miR-29 exerts its 
positive effect on osteoclastogenesis may aid in the design of therapeutic strategies for 
bone diseases associated with alterations of the osteoclast compartment. 
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miRNA-based therapeutics in clinical trials. 
At the time of this writing, two miRNA-based therapeutics have been used in 
clinical trials. Miravirsen, a locked nucleic acid (LNA) inhibitor oligonucleotide for miR-
122, is the most clinically advanced miRNA-based drug. Currently in clinical phase 2a 
trial, Miravirsen is designed to repress miR-122, which is highly expressed in the liver. 
Here, miR-122 targets the hepatitis C virus (HCV) in infected patients and protects it 
from degradation. By sequestering miR-122, Miravirsen blocks HCV replication, and 
repress the viral infection (Santaris Pharma A/S) (165). 
Recently, the first miRNA mimic entered clinical phase 1 trial. MRX34 is a 
double-stranded RNA mimicking the sequence of miR-34. miR-34 is down-regulated in a 
variety of tumors, and more than 20 oncogenes were identified as direct targets. MRX34 
is delivered using an amphoteric liposomal carrier formulation, which is positively 
charged in an acidic environment. Since tumors often have low pH, this design facilitates 
MRX34 uptake in cancer cells, but not in normal cells (miRNA Therapeutics, Inc.) (166). 
 The development of therapeutics based on miRNAs faces many challenges. In 
pre-clinical studies, most approaches have used oligonucleotides designed to inhibit a 
specific miRNA or to mimic its sequence. For safety reasons, this strategy is usually 
preferred to the use of viral expression constructs. However, chemical stabilization of the 
oligonucleotide RNA molecules is necessary to avoid their degradation and decrease 
immunogenicity (167). Another difficulty centers on the delivery of the miRNA 
therapeutic. 
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Delivery of miRNA-based therapeutics. 
 The most recent delivery methods for nucleic acid-based drugs, investigated 
primarily for small interference RNAs (siRNAs), consist of the conjugation of the RNA 
molecules with cationic lipids or natural and synthetic polymers, to form nanoparticles. 
Lipids and polymers may be used both as delivery carriers and as modification agents. 
Common polymers used include polyethylenimine (PEI), composed of repeated amine 
groups, poly(lactide-co-glycolide) (PLGA), chitosan, atelocollagen, and protamine. 
Alternatively, the RNA sequences can be fused to proteins or aptamers, which are 
structured nucleic acid or peptide molecules, which can be recognized by specific surface 
receptors. These delivery methods have been explored in several cell types, including 
hepatocytes, breast cancer cells, T lymphocytes, and osteoblasts (167). 
 In selecting an appropriate delivery system, it is important to choose an approach 
that is efficient, but that also allows the targeting of the nucleic acid to the tissue of 
interest. Localized delivery and release of the miRNA mimics or inhibitors is necessary 
to reduce systemic side effects. For the same reason, in the perspective of using miRNAs 
for the development of therapeutics, the identification of miRNA target genes is critical. 
Although the function of a specific miRNA is known in a particular cell type or tissue, 
unpredictable effects could occur due to the regulation of unknown targets. 
In the skeleton, cell-specific delivery is especially difficult because of the 
complexity of the microenvironment. Recently, RNA-based molecules have been used to 
improve bone formation in an animal model. siRNA for pleckstrin homology domain-
containing family O member 1 (Plekho1) was selectively delivered to osteoblasts, but not 
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to osteoclasts, using cationic liposomes conjugated with six repetitive sequences of 
aspartate, serine, serine, (Asp,Ser,Ser)6 (168). This oligopeptide was shown to 
preferentially bind lowly crystallized hydroxyapatite and amorphous calcium 
phosphonate, which are characteristics of bone-forming surfaces (169). In contrast, a 
sequence of eight repeats of aspartate (Asp8) has strong affinity for highly crystallized 
hydroxyapatite, such as that found on osteoclast-rich bone-resorbing surfaces (170). 
These differences allow the specific targeting of surfaces covered mainly by osteoblasts 
or osteoclasts. 
In another study, siRNA against RANK was delivered to osteoclast precursors 
and mature osteoclasts in vivo, using PLGA microparticles and calcium-based injectable 
cement. Here, the siRNA retained its biological activity, and repressed the expression of 
RANK (171). In vitro, siRNA for RANK was shown to inhibit osteoclast formation and 
bone resorption activity (172). However, the efficacy of these molecules on osteoclast 
differentiation and function has not been tested in an in vivo model.  
Targeting common precursors, rather than differentiated osteoclasts, could 
represent another strategy for affecting osteoclast number. A few studies have selectively 
delivered siRNA molecules to leukocytes, taking advantage of antibodies directed against 
cell-surface antigens, such as integrin lymphocyte function-associated antigen-1 (LFA-1), 
fused to protamine molecules (173). In another report, Peer and colleagues delivered 
siRNA by means of liposomes covalently bound to anti-β7 integrin antibodies (174). 
Although these and other strategies can be used to deliver RNA-based drugs to 
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hematopoietic cells, selective targeting of cells of the monocytic lineage has not been 
reported. 
We showed a positive role for miR-29 in the osteoclast lineage, and demonstrated 
that its knock-down strongly affects osteoclast differentiation in vitro. Our data suggest 
that miR-29 could be targeted in the development of therapies for pathological conditions 
characterized by extensive, aberrant bone resorption. Systemic bone loss can be caused 
by excessive osteoclast number or activity, as in the case of post-menopausal 
osteoporosis. In contrast, localized bone loss can occur in rheumatoid arthritis and 
periodontal disease, and cause joint damage and tooth loss. miRNA-based therapies 
appear especially appealing for structures like the articular joints or the mandible, since 
the delivery of the miRNA mimics or inhibitors could be confined to these localized 
areas. 
However, our laboratory and others previously demonstrated that miR-29 also 
mediates the differentiation of osteoblasts. Therefore, in the use of miR-29 inhibitors to 
repress osteoclastogenesis, it would be particularly important to deliver the RNA 
molecules only to the bone resorbing cells. Potentially, the delivery of a miR-29 inhibitor 
to the bone remodeling units would result in reduced bone turnover, leading to increased 
bone fragility. 
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Conclusions 
 
The studies presented in this dissertation are unique in that we described the 
molecular mechanisms by which a family of miRNAs, miR-29a, -29b, and -29c, supports 
osteoclastogenesis, and we identified six novel target genes that may mediate this 
function. This work not only expands our knowledge of the role of miRNAs in the 
osteoclast lineage, but it also helps us better understand the basic molecular workings 
regulating cell differentiation, which could be applicable in other cell types. 
In addition, we profiled miRNA expression in a primary bone marrow population 
enriched for osteoclast precursors, and characterized how this profile changes during the 
early, middle, and late phases of osteoclastogenesis. We showed that clusters of 
differentially expressed miRNAs could potentially regulate numerous genes involved in 
actin reorganization and cell motility. Thus, we highlighted novel miRNAs that may play 
a critical role in osteoclasts. 
Maintaining the delicate balance between bone formation and resorption is critical 
for bone health. In pathological conditions this becomes unbalanced, and the 
development of therapeutic strategies able to restore this homeostasis relies on a thorough 
understanding of the molecular mechanisms of osteoblast and osteoclast differentiation. 
Our research contributes to this goal by providing new data on the function of miRNAs in 
the osteoclast lineage. 
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